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Abstract 
Studies point that patient adherence to medication is still a big challenge to the pharma 
industry, since 50-60% of chronic patients in the USA admit not to comply with the 
prescribed therapy. For this reason pharmaceutical companies have turn their R&D 
efforts to patient centric dosage forms aiming to improve therapeutic outcomes by 
improving patient compliance. 
One of the most promising technologies in this field are Oral Thin Films (OTFs), a solid 
dosage form for fast or sustained drug release in the oral cavity. Currently there are 
almost 10 products in the market and OTFs are generally well accepted by the 
population, due to their unique advantages. OTFs are easy to swallow, there is no need 
of water for the administration, they present a good taste and mouth feel and they may 
improve medicines safety through a reduction in their side effects. Due to these 
advantages they are particularly suitable for those patients with swallowing difficulties, 
such as the elderly, children and patients with neuron motor diseases. 
In this dissertation it is explored the manufacturing process of OTFs, in order to identify 
the necessary requisites for the implementation of a new manufacturing facility for the 
development and commercial scale production of OTFs. Thereby, a specific aim of this 
work was to understand the types of equipment necessary, how they work and which 
models are available in the market. 
Through an intense research and procurement process it was possible to analyze 39 
different types of equipment, to study their critical process attributes and to estimate 
their capacity. Finally we were able to determine the necessary investment, to outline 
the design of a manufacturing facility and to trace a road-map for its implementation. 
 
Keywords: Pharma Industry, Manufacturing, Engineering, Oral Thin Films. 
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Resumo 
Estudos mostram que a adesão dos pacientes à medicação é ainda um grande desafio 
para a indústria farmacêutica, sendo que 50-60% dos pacientes crónicos nos EUA admite 
não cumprir devidamente a terapêutica prescrita. Desta forma, as empresas 
farmacêuticas têm direcionado a sua investigação para novas formas farmacêuticas 
centradas no paciente. 
Uma das tecnologias mais promissoras neste campo é os Oral Thin Films (OTFs). Os OTFs 
são uma forma farmacêutica sólida para libertação rápida ou controlada do 
medicamento na cavidade oral. Atualmente há já cerca de 10 produtos no mercado, 
sendo que esta nova forma farmacêutica tem sido bem recebida pela população, devido 
sobretudo às suas vantagens únicas. São fáceis de engolir e não há necessidade de beber 
água, têm sabor agradável e podem melhorar a segurança do medicamento, ao reduzir 
os seus efeitos secundários. Devido a estas vantagens, os OTFs são particularmente 
adequados para administração em pacientes com dificuldades em engolir, como idosos, 
crianças e pessoas com doenças neuro-motoras. 
Nesta dissertação é explorado o processo de fabricação de OTFs, com o objetivo de 
identificar os requisitos necessários para a implementação de uma nova unidade de 
fabrico para o desenvolvimento e produção comercial de OTFs. Assim, uma parte 
específica deste trabalho foi tentar perceber qual o tipo de equipamento necessário, 
como funciona e quais são os modelos disponíveis no mercado. 
Através de uma intensa pesquisa e procura de mercado, foi possível analisar 39 
equipamentos de vários tipos, estudar os seus aspetos críticos e estimar as suas 
capacidades. Por fim foi possível determinar o investimento necessário, esboçar o 
desenho da nova unidade e traçar um road-map para a sua implementação.  
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1 Introduction 
1.1 Scope 
This dissertation is the result of the project carried out by the student Ricardo Filipe 
Morgado de Sousa for the conclusion of the Master’s Degree in Biomedical Engineering. 
The project started in November of 2014 and corresponded to a trainee of 9 months in 
the pharmaceutical company Bluepharma, Indústria Farmacêutica S.A.  
The supervision of the work developed was in charge of Professor Sérgio Simões from 
the Faculty of Pharmacy of the University of Coimbra and Dr. Cláudia Silva, Head of 
Research of Bluepharma. 
The project was named “Conception and implementation of a new facility for the 
manufacture of a novel dosage form”. 
1.2 Motivation 
It was always been an intention of mine to have an enterprise experience while I was 
studying in the University of Coimbra. It is my vision that we should do different things 
in college that can contribute to other skills that we will not get inside the classrooms. 
That’s why I choose to go abroad under the Erasmus program, to get involved in 
Associação Académica de Coimbra and to participate in several national and 
international programs. 
As a future engineer, it was also my intention to try to have an enterprise experience in 
an industrial company. In addition, I was always interested in the pharmaceutical 
industry in particular, because of the importance that plays in the World and by the 
extreme rigor that is associated to this area. 
All of this made me send my curriculum vitae to Bluepharma. I knew the success history 
of this young, prestigious and innovative company in Coimbra and I was sure that it 
would be the best option to do my Master’s project. All of these are the motivations 
that made me accept such a challenging project, a decision I don’t regret at all. 
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1.3 About Bluepharma 
Bluepharma is a privately owned pharmaceutical company, located in Coimbra, 
Portugal, devoted to the development, manufacturing and distribution of 
pharmaceutical products. It was launched in 2001 when a group of experienced 
professionals, all related to the pharmaceutical field, decided to acquire Bayer’s 
industrial unit in Coimbra.  
Starting as a pure CMO, Bluepharma rapidly moved into the development of their own 
generic products and more recently to innovative products and business approaches. 
We offer an integrated approach on the process of drug discovery and development, 
including innovative research on new chemical and therapeutic entities, based on novel 
platforms for the delivery of known drugs, supported by a highly qualified team, with 
top regulatory expertise in national and international markets, in medicines and medical 
devices. 
The state-of-the-art manufacturing site is dedicated to oral solid dosage forms and is 
approved by the most demanding regulatory authorities worldwide: FDA (USA), EU-
GMP, Korea FDA (MFDS), Taiwan FDA, Iran TGA. 
Since its launch, Bluepharma has based its activity in four main principals: Innovation, 
Quality, Internationalization and Investment. To follow this principles we’ve been 
building strong relations with major key players of the international pharmaceutical 
market (pharmaceutical companies, labs, research centers and universities), with whom 
we established successful partnerships through B2B and B2C models. Bluepharma is 
chiefly identified for its Research and Development, marketing expertise, lean 
operational principles, economy of scale and quality standards. 
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2 Theoretical Background  
 
2.1 Patient centric dosage forms 
Studies from 2010 show that in the USA the patient adherence to therapies for chronic 
conditions is low, in the order of 50-60%[1]. 
There are several types of factors that influence the adherence of a patient to a certain 
therapy that can be related with the patient himself or even with its social status. Some 
of those impacts are described in the Figure 1. 
 
Figure 1 - Factors that influence patient adherence to therapy [2]. 
 
To give a response to this problem, the pharmaceutical industry has been seeking new 
solutions in order to improve the patient compliance to therapy.  
Figure 2 - Some examples of strategies to improve patient compliance [3], [4]. 
 
New formulations to improve 
product profile
•Side effects reduction
•Taste masking
New delivery technologies
•Orodispersible tablets, edible films
•Transdermal patches
•New inhaled formulations, sprays 
Smart packaging solutions
•packs with reminder function
•Easier to open/carry packages
Use of friendlier language for 
information
•Use of mobile apps and web sites to 
raise awareness and monitoring 
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In the Figure 2 it can be seen some examples of strategies that have been developed. In 
this project we will explore a novel oral drug delivery system. 
New drug delivery systems represent one of the major research areas in the 
pharmaceutical and biomedical industries [5]. Nowadays, pharma industry seeks to 
improve drug stability, oral bioavailability and to decrease the incidence of drug’s side 
effects [6]. Moreover some of these new dosage forms enable to increase its efficiency 
through a controlled release of the drug and may improve patient compliance.  
As commonly known, the oral route of drug administration is the most preferred by the 
general population [7]. However 28% of the patients have some problems in swallowing 
tablets and capsules (dysphagia) [8]. These patients include the elderly who have 
difficulty ingesting conventional oral dosage forms mainly due to hand tremors and 
dysphagia; children who are afraid to take the solid dosage forms due to the muscular 
and nervous underdevelopment; mentally ill; patients with developmental delay and / 
or less cooperative; patients with treatment regimens with low intake of liquids; 
patients with reduced salivary secretion and travelers who may not have easy access to 
the water [9]. Also dysphagia is associated with several medical conditions, like AIDS, 
Parkinson’s, head and neck therapy by radiation, thyroidectomy and several other 
neurological conditions [10].  
 Oral drug delivery systems represent more than 52% of the global market share of all 
the drug delivery systems and it is estimated that their market value will reach 90 billion 
euros by 2016 [11]. All these reasons make the oral drug delivery systems a very 
appealing area to invest, in a market with strong competition and billions of investments 
in drug development. 
In this project, we will explore the manufacturing process of one particular novel oral 
dosage form that is currently being developed at Bluepharma, Indústria Farmacêutica, 
S.A. – Oral Thin Films (OTFs). 
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2.2 Oral Thin Films 
In the late 1970s, the first fast dissolving drug delivery systems were developed, in order 
to work as an alternative to capsules and tablets, namely for geriatric and pediatric 
patients [10]. Fast dissolving thin films appeared in 2001, first as breath fresheners, 
when Pfizer first launched the Listerine® PocketPaks. Nine years would have to pass so 
the first OTF accepted for medical prescription was released on the market – Zuplenz® 
was launched in 2010 in the United States [12].  
Currently, there are several types of OTFs. Depending on its purpose of action they can 
be named by the following terms [4]: 
 Orodispersible Films: 
o Non-mucoadhesive 
o Mucoadhesive: absorption in the gastrointestinal tract 
 Oral-Mucosa Films (Buccal, Sublingual or Palatal Films): 
o Mucoadhesive: absorption in the oral cavity, for fast onset action. 
Generally speaking, Oral Thin Films are a solid dosage form for fast or sustained release 
in the oral cavity. The USFDA describes it as a flexible polymeric strip that contains active 
pharmaceutical ingredients (APIs), which are intended to be placed on the tongue for 
fast disintegration for dissolution in the saliva before  swallowing for delivery in the 
gastrointestinal tract [13]. 
The user-friendly characteristics of OTFs make it a good option for specific target groups, 
as  very young children and geriatric population [4]. Also patients with dysphagia and 
motor neuron diseases can benefit from this dosage form. Some of the advantages for 
the patients are [4], [14]: 
 No need of water or spoon for administration, compared with tablets or syrups, 
and no need of chewing; 
 Dose accuracy, because each strip as the precise dose that should be 
administrated; 
 Good taste due to taste masking agents in the formulation, that makes it more 
acceptable for children; 
THEORETICAL BACKGROUND 
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 Easy to carry and to keep, due to its small size, flexibility and packaging options; 
 Due to its fast dissolution, it’s difficult to spit out, what makes it a suitable option 
for difficult patients that tend to reject the medication. 
Clinically speaking, there are also clear advantages of using OTFs as a delivery system 
[4], [14]: 
 The fast onset action allows the drug to enter in the systemic circulation directly 
in the mouth;  
 Improved oral bioavailability and reduced side effects. Some OTFs promotes the 
absorption of the drug in the oral mucosa reducing hepatic first pass effects and 
in these cases the drug dose can be reduced; 
Oral Thin Films can also be an advantage to pharmaceutical companies from the market 
point of view. If an OTF product presents a different pharmacokinetic profile compared 
with the product already in the market, it is considered a new medicine and it follows 
the FDA 505(b)(2) approval pathway, where a new clinical study it’s required but 
preclinical toxicity studies are not needed, because the molecule it’s the same. This 
means that the approval process it’s faster and plus, an exclusivity marketing 
authorization of 3 to 5 years it’s can be conceded, so no competitor can launch that 
same drug in OTF dosage form during the defined exclusivity period [4], [15].  
Nonetheless, as all dosage forms, OTFs have also some limitations. 
The main limitation is the small amount of drug that may be incorporated per OTF. 
Although some companies managed to introduce up to 50% of drug substance per film 
weight, the best case reported was Novartis Gas-X Strips® with 62,5mg of drug 
substance into a strip [4], [14]. This means that high doses medicines cannot be 
developed in OTFs. 
 
2.2.1 Formulation 
One key component of OTFs is the film forming polymer. In fact, OTFs are basically a 
polymeric matrix that can have one or more polymers with different properties, 
depending on the characteristics that we want to incorporate in them, like the drug load 
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capacity, disintegration time, mucoadhesiveness, elasticity and others. Currently, the 
polymers used can be natural derivative polymers of cellulose or starch but can also be 
used semi-synthetic or synthetic polymers [4]. The choice of the most suitable polymer 
it’s one of the most important steps in the development of OTFs.  
Beside the drug substance and the polymer, other ingredients are normally used in the 
formulation of OTFs, like sweetening agents or plasticizers. The Table 1 resumes the 
ingredients and their usual percentage in a typical OTF. 
 
Water soluble polymer 45% ww 
Drug 5 % to 30% ww 
Plasticizers 0-20% ww 
Surfactants q.s. 
Sweetening agent 3% to 6% ww 
Saliva stimulating agent 2% to 6% ww 
Fillers, colorants, flavors, etc. q.s. 
 
Table 1 - Typical composition of an oral thin film [16]. 
 
In both formulation and manufacturing processes there are several critical quality 
attributes (CQA) that should be considered in the development of OTFs. These 
parameters must be defined in the beginning of the development process. Some of 
those CQAs are [4]: 
 Physical strength: the OTF must present suitable mechanical properties so it can 
easily resist to the manufacturing process and consequently handling of the product. 
Properties like tensile strength or elongation at break must be tested and the 
appropriate values mostly depends on the polymer that is being used; 
 Stability: drug substance stability (physical, chemical and thermal) is very important 
and can directly influence, for example, the manufacturing process, its conditions and 
the choice of the polymeric matrix and the packaging material. The stability of the 
product will determine, among other things, its shelf-life and the storage conditions;   
 Appearance: characteristics like the size, the color and shape must be considered. 
For example, for OTFs that are intended to be placed under the patient’s tongue, the 
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size should be small enough to be comfortable because the area available is very 
small; 
 Drug release profile: it depends if the OTF is supposed to be dissolved quickly or to 
be slowly released, or if the absorption should occur in the oral mucosa or in the 
gastro intestinal tract; 
 Residual water content: an excess or lack of water can interfere with the mechanical 
properties of the OTF. Each formulation should have the right amount of water to 
ensure the desired mechanical properties. Suitable packaging material should be 
taken into account to avoid water transference between the OTF and the surrounding 
environment; 
 Organoleptic characteristics: OTFs can be delivered with a certain flavor 
incorporated, what make it a good option for pediatric patients. However, the choice 
of a pleasant option depends on the taste of the drug substance. Also, the market 
target must be considered because flavor preferences can vary from region to region 
and from age to age; 
 Dose uniformity: the dose uniformity depends on the formulation but also on the 
size and thickness of the product. These parameters should be constantly controlled 
in the manufacturing process so slight adjustments may be carried out.  
 
2.2.2 Manufacturing Process 
There are different manufacturing processes which are well documented in the 
literature: 
 Solvent casting; 
 Hot melt extrusion; 
 Semisolid casting; 
 Solid dispersion extrusion; 
 Rolling. 
Solvent casting and hot melt extrusion are the most commonly used. 
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Solvent casting 
Solvent casting, also known as film casting, is the most used manufacturing process for 
OTF, being  a relatively simple and low cost method [17]. In this process, an aqueous or 
hydro-alcoholic mixture of excipients and drug substance(s) is casted on a surface, 
where the solvents evaporate so the mixture becomes a solid thin film. After this, the 
film is cut in strips with the desired size and shape [4]. During the internship in 
Bluepharma, I had the possibility to see the manufacturing of OTFs in the laboratory, 
using this method. The process goes as described below: 
 The mixture is prepared; 
 A sheet of a release liner is placed in the casting machine; 
 The mixture is spread along the substrate (release liner) with a proper slot or 
knife with a uniform thickness; 
 The  casting machine is heated in order to transfer the necessary energy to the 
solvents evaporation; 
 In the end, the release liner with the OTF on top is removed from the coating 
equipment and it is cut into individual OTF with the desired dimensions; 
 Finally, the release liner it’s peeled off manually from every strip and each 
individual OTF is placed into an individual pouch that is sealed by heat.  
In a higher scale, the casting machines are more complex, as showed in Figure 3. 
 
 
Figure 3 -Schematic of the solvent casting method in a continuous machine [18]. 
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Like the image displays, the release liner roll is placed on the left and it is slowly 
unwinded. Then it passes through an applicator that contains the formulation where the 
mixture passes through a small clearance that makes the mixture to be spread with the 
same thickness along the release liner. The release liner continues moving and enters in 
a drying zone where the solvents are evaporated. Finally, the liner with the solid film is 
winded in a new roll. 
This method is appropriate for OTFs with high sensitive APIs, namely because the drying 
process is made under relative low temperatures [18]. 
The machines responsible for this process at high production scales are called coating 
machines. Thereby this process it’s commonly known as coating process, definition that 
we will use in this dissertation. 
Hot melt extrusion 
This method consists in shaping a mixture of polymers, drug substance and other 
ingredients into a film strip through a melting process that melts all components [4]. 
 
Figure 4 - Diagram of the hot melt extrusion process for the production of OTFs [18]. 
As seen in the Figure 4, the drug and the other ingredients are added in the solid state. 
The extruder then homogenizes and heat the ingredients by the action of the extruder 
screw that moves itself thanks to the motor, so the ingredients are mixed and fused. 
Finally, the melted material is forced to pass by a flat die that presses the resulting film 
into the desired shape  [18], [19]. 
There are some limitations in this method, mainly because the ingredients are subject 
to high temperatures which can cause thermal degradation. Plus, all the ingredients 
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must be completely devoid of water or other volatile solvents. If not, the uniformity of 
the film can be affected [18]. From the advantages point of view, this method is 
appropriate for anhydrous processes and it tend to present better results in terms of 
content uniformity [19]. 
Semisolid casting, Solid dispersion and Rolling 
The semisolid casting is a method where a solution of a water-soluble polymer is added 
to a solution of acid insoluble polymer, previously prepared under certain conditions. 
Finally a gel mass is prepared by the addiction of a plasticizer and it is casted into films 
using a heat source [15]. 
The solid dispersion method consists in the extrusion of immiscible components with 
the drug, so a solid dispersion is obtained [19].  
Finally, in the rolling method a solution or suspension composed mainly of water and 
alcohol, also containing the drug, is rolled on a carrier. The films are then dried on the 
rolls [15]. 
 
2.2.3 Packaging of OTFs 
OTFs can be packaged in single units or multiple dose packages.  Figure 5 shows some 
examples of how OTFs can be packed. 
 
Figure 5 - One OTF and different types of packaging material. 
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Some examples of multiple unit options are the dispensers and the continuous roll 
dispensers. Some of these solutions are even patented [14]. 
There are advantages and disadvantages in the way the films are packed.  A single unit 
package offers more stability and avoid possible fusion of the strips when compared 
with multi dose solutions. Nevertheless, it is more expensive to produce single unit 
solutions, mainly because more packaging material is necessary increasing the cost. The 
multiple dose packaging solutions are more expensive to develop, but less expensive to 
produce in high quantities [20]. 
 
Web Converting and Primary Packaging 
Web converting and primary packaging are two different processes, although they occur 
in the same equipment in the case of OTFs. The process it’s described in the Figure 6. 
 
 
Figure 6 - Diagram of the web conversion and packaging in a primary packaging machine [20]. 
 
Figure 6 represents a web converting and primary packaging machine. At the laboratory 
scale the cut and packaging of the OTFs may be done manually.  
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The mother roll is the roll that comes from the solvent casting machine, as seen before. 
In the first step this roll is divided in two or more lanes, which operate simultaneously. 
Pilot machines, as we will see, normally just operate with one lane. The web keeps 
running and then it is cut into individual strips with the desired size and shape. The 
release liner is then peeled off from the cut film. All this process is called web conversion, 
because the film roll is converted into small strips.  
After that, each strip is placed into a small individual pouch, which is then sealed. This, 
of course, in the case of single packaging process. 
Secondary packaging 
The secondary packaging is the process were the products are packed in the final 
packaging format, conventionally in a carton box. It is done normally by cartoning 
machines placed in the end of the primary packaging line. This equipment it’s similar to 
the ones used in the production of other more conventional solid dosage forms, like 
capsules or tablets. 
 
2.2.4 Market Perspectives 
Since 2013, more than 80 OTFs brands were launched, mainly in the USA and Asia. 
However, most of this brands launched are Over-the-Counter (OTC) products. As we 
have seen, just in 2010 was launched the first OTF for prescription (Rx) [14]. This first 
product, Zuplenz ® (Ondansetron PharmFilm®) in the USA and Setofilm® (Ondansetron 
RapidFilm®) in Europe, is an OTF for the prevention of nausea and vomiting and in its 
first year it conquered a wide share of a market that generated 1.9 billion dollars in that 
year [21]. The second Rx product launched was approved one month later. The 
Suboxone® sublingual film, is an OTF with two drug substances (buprenorphine and 
naloxone) for the opioid addiction, and was the confirmation of the success that OTFs 
can have in the Rx market, generating sales of 513 million and 1.5 billion in 2011 and 
2012 in the USA, respectively.  
It was estimated that OTF Rx market experimented an annual growth of 17.1% from 
2009 to 2014. Also, during the period from 2009 to 2019 it is expected that the industry 
value added (IVA), an indicator that measures the contribute of an industry to the overall 
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economy, will represent an annual growth of 13.6% in the USA [22]. This is explained by 
the crescent number of companies investing on this new dosage form. Currently there 
are 10 products launched in the market and 29 are in different stages of development 
[23]. 
There are many advantages, as seen, in this technology. The principal therapeutically 
areas where companies are investing are [19]: 
 Pediatrics; 
 Geriatrics; 
 Gastrointestinal diseases; 
 Nausea; 
 Pain; 
 Drug Addiction; 
 Motor-Neuron Diseases. 
This is a market of partnerships between companies dedicated to the manufacturing of 
films, contract manufacturing organizations (CMOs), companies dedicated to the 
discovery of new chemical entities or developing new uses for existing drugs and also 
companies searching for new ways to extend their drugs lifecycle. This strategy results 
in lower risk of investment but also shared revenues. It can be said that there are two 
main players in the OTF market, the technology owners and the marketing partners [21]. 
The main players and their technologies are [21], [23]: 
 MonoSol Rx LLC: PharmFilm®; 
 Applied Pharma Research (APR) and  Tesa Labtec: RapidFilm®; 
 BioDelivery Sciences: BEMA®; 
 FFT Medical: Oral Transmucosal Film; 
 IntelGenx: VesalFilm®. 
All these facts demonstrate that OTF delivering systems are a trending technology in the 
pharmaceutical market. However, the competition will probably grow as the market 
becomes more receptive to it. Thereby it’s important to understand deeply the 
THEORETICAL BACKGROUND 
18 
 
necessities and opportunities of the market and present solutions that can represent a 
differentiate factor rot e company. 
Also it must be considered that OTFs manufacturing is a less expensive process when 
compared with other complex oral delivery systems, but it is more expensive that the 
manufacturing processes of more conventional dosage forms [21]. 
 
  
THEORETICAL BACKGROUND 
 
19 
 
 
 
 
 
 
 
CHAPTER 3 
 
Objectives 
  
OBJECTIVES 
20 
 
3 Objectives 
The aim of this project was to identify all the necessary requirements for the 
implementation of a new manufacturing facility for a novel oral dosage. Moreover the 
specific objectives of this project were: 
 To identify the main manufacturers (CMOs) of OTFs; 
 To identify the major suppliers of mixing equipment, coating equipment and web 
converting and primary packaging equipment; 
 To make a procurement process in order to obtain the specifications and 
budgetary quotations of the equipment mentioned on the previous point, for 
pilot and commercial scale; 
 To analyze each equipment in order to determine their critical quality and 
process attributes and to estimate their annual capacities; 
 To determine the necessary capacity of the new manufacturing facility in order 
to meet Bluepharma’s OTF forecasts; 
 To trace a road-map for the acquisition of equipment and to estimate the 
necessary investment; 
 To outline a manufacturing facility of OTFs that have laboratory, pilot and 
industrial scale. 
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4 Methodology  
Oral Thin Films are a novel dosage forms with a particular manufacturing process that is 
different to the manufacturing process of tablets or capsules, the conventional ones. For 
this reason it is very important to identify the type of equipment used, and to 
understand the critical process parameters in order to be able to design a new 
manufacturing facility dedicated to this dosage form. 
The first step was to look to the competitors in this area in order to find the right 
companies with suitable equipment solutions for the three phases of OTF manufacturing 
process: Mixing, Coating web converting and Primary Packaging.  
In the end, it’s our hope to answer to three simple but crucial questions: 
- What do we need in terms of equipment?  
- How does it work?  
- When do we need it?  
 
4.1 Search Method 
To answer the first question, it’s important to study and characterize OTF market. 
Moreover, the study of this particular environment allowed us to understand who is 
investing in this technology and who are the main suppliers of equipment for the 
production of OTFs. 
Thereby, it is important to have a suitable end efficient search methodology in order to 
get proper, reliable and traceable information. 
First of all, we divided our search in Macro Data and Micro Data. 
By Macro Data we mean non-specific information that characterizes OTF technology, its 
manufacturing and development processes and its market as a whole. For this part of 
our search several web sites dedicated to this kind of information were used (see Table 
2). 
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Scientific Technology and Manufacturing Economic Others 
PubMed 
B-On 
FiercePharma 
PharmaTek 
PharmTech 
in-Pharma 
Drugs.com 
IBIS World 
Root Analysis 
Frost & Sullivan 
Markets and Markets 
CMO Locator 
LinkedIn (discussion 
groups) 
Table 2 – List of websites and platforms used for macro data search, divided by area. 
 
Through this engines, we were able to find studies, reports, news and articles containing 
very important scientific, technological and economical know-how.  
In what concerns Micro Data, a specific research was used in order to obtain information 
about OTF products, competitors and equipment suppliers. The list of sources can be 
found on Table 3.  
 
Databases Suppliers and CMOs Exhibitions / Websites Others 
Cortellis 
Newport 
 
Press Releases 
Products overall 
specifications 
Annual Reports 
Interpack 
PharmTech 
CPhI 
FCE Pharma 
InterPhex 
Pharm Complex 
ACHEMA 
European Coating Show 
Google 
LinkedIn (companies 
profiles) 
YouTube (equipment 
videos) 
Table 3 - List of websites and platforms used for micro data search, divided by area. 
 
It’s important to make a reference to Cortellis and Newport databases. These engines 
are products of Thomson Reuters, one of the biggest media and information group of 
the world. These tools allowed to retrieve precise information on pharmaceutical 
products, such as medical indications, sales forecasts, deals, companies’ involved, 
patent information, press releases and analysis reports, stage of development and 
others. In the Figure 7 it’s possible to see a print screen of the Cortellis database. 
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Figure 7 - Snapshot of Cortellis database. 
The biggest difference between these two platforms is that Cortellis has information 
about products still in development, while Newport presents information about 
products already in the market.  
 
 
Figure 8 - Snapshot of Newport database. 
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The Figure 8 it’s a print screen of Newport. These tools were used with the needed 
permission, once they are not license-free. 
Moreover, we visited the websites of some of the biggest pharma events in the world. 
This quest was very helpful, because it is possible to search for exhibitors by area of 
interest and retrieve information about them. 
 At last, but not least, we lead an individual investigation to the identification of possible 
CMO’s and suppliers that we identified in the previous steps. 
A note also for the more common and social engines, such as LinkedIn, Google or 
YouTube, that were also a precious help to get information. On LinkedIn we found 
discussion groups about OTFs, were people connected to this area post and share 
information about this technology. In what concerns YouTube we used it to watch some 
videos of the equipment working, founded in some of the suppliers’ pages.  
Finally, relevant data was selected and then analyzed among an enormous amount of 
information.  
 
4.2 Procurement Process 
After the initial search, we identified a group of possible suppliers for the equipment 
necessary to the production of Oral Thin Films. After this we followed the following 
method to reach the final group of suppliers: 
 Research phase: identification of possible suppliers and CMOs; 
 Individual Analysis of the identified suppliers: First Selection; 
 Direct contact with the first selected suppliers: Final Group of Suppliers. 
We followed this three step method in order to reach a final group of suppliers that 
fulfilled the following requirements: 
 Suitable equipment for our needs: mixing, coating, web converting and primary 
packaging equipment; 
 Experience with OTFs and TDDS; 
 Experience in the pharma and medical industry; 
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 Compliance with quality requirements, namely FDA and EU GMP requisites. 
After the identification of the possible suppliers, we embarked in a more profound 
individual analysis by investigating each supplier profile. We searched the information 
available on their websites, the industry databases and press releases. We also analyzed 
each competing CMO with the expectation of perceiving their equipment suppliers. This 
search was more difficult by the fact that pharmaceutical companies are much closed 
about their processes and technologies. Some of these information can be seen in the 
appendix A. Nevertheless we found some important information in some press releases 
and internal reports. In the end of this step, we had selected a group of 21 companies 
as potential suppliers for the OTF manufacturing equipment.  
The next step was to contact all these companies via e-email (see Appendix). In this first 
contact we presented Bluepharma and the technology for which we needed the 
equipment and we asked for: 
 Available equipment for pilot scale and commercial scale; 
 Technical specifications including output and total capacity for a standard sized 
strip; 
 Lead time, budget quotation and payment conditions for each equipment; 
 Type of support (e.g. training, installation, documentation, validation, 
qualification, etc.).  
This was a continuous process and along the way companies were excluded for several 
reasons. In the end we had a final group of 13 suppliers that presented official proposals 
for analysis.  
 
4.3 Identification of the Critical Requisites 
It was an objective of this project to deeply how the three types of equipment work and 
what are the critical aspects that determine their performance and output. It’s 
important to say that the vast majority of the input information come directly from the 
suppliers that were selected. 
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4.4 Capacities Estimation 
To determine the capacity of each equipment we followed a rigorous method that is 
defined in the next pages. This work was performed for the coating and primary 
packaging equipment. 
4.4.1 Coating Equipment 
As seen before, this equipment is used to coat the liquid mixture of excipients and drug 
substance in a release liner to form a film.  
As we can easily understand, it’s the velocity that determines the output of the 
equipment. But as we’ll see in the next chapter, the velocity in the coating machines is 
determined by the drying process. 
Every supplier gave us their claimed process velocity. The problem was that they were 
considering different type of formulations, so these velocities were not possible to 
compare. Each formulation will behave differently. For example, a formulation with a 
high percentage of water will take more time to dry than one with less amount of water. 
So, if it takes more time to dry the velocity will be slower and the output smaller. 
Once all the equipment used the same drying technology (hot hair in a closed system 
dryer), we applied the knowledge that we had about our formulation in order to get a 
drying time that we could use in our predictions. 
We knew at this point that Bluepharma’s formulation takes 20 to 30 minutes to dry a 
sample at 40ºC by contact heating from bellow. We crossed this information with the 
opinions of our suppliers for this type of situation, in order to get a realistic time value 
to dry our formulation. 
Thereby we considered a time of 𝑇 = 10 𝑚𝑖𝑛 to dry our formulation in a coating 
machine. 
As we will see further, the factor that is directly related with the increase of the capacity 
is the dryer length. It is easy to understand, the higher is the drying path we have the 
faster the process can go.  
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If we consider 𝑋 as the dryer length of the equipment and 𝑋𝑖 the beginning of the dryer 
(zero), we can relate it with the drying time in order to get the velocity of the process 
for each equipment: 
𝑋 = 𝑋𝑖 + 𝑉 x 𝑇 
Eq. 1 
If we consider 𝑋𝑖 = 0 𝑚, 
𝑉 =
𝑋
𝑇
 
So, 
𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
𝐷𝑟𝑦𝑒𝑟 𝑙𝑒𝑛𝑔ℎ𝑡 (𝑋)
𝐷𝑟𝑦𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 (𝑇)
 
Eq. 2 
We this information we were able to calculate the area produced by a coating 
equipment, by applying the following equation: 
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑓𝑖𝑙𝑚 = 𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 x 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 x 𝑊𝑒𝑏 𝑊𝑖𝑑𝑡ℎ 
Eq. 3 
Where the Web Width is the accepted release liner width of the equipment and the 
Working Time the time that the machine operates. 
Working Time 
The objective of these estimations was to know if the equipment being analyzed had the 
necessary capacity to ensure the production of the Bluepharma’s OTFs according to the 
internal forecasts (on a year basis). All the suppliers informed us that both pilot and 
industrial equipment can run 24 hours per day, and that it’s normal that the production 
run in 2 or 3 shifts per day, normally of 8 hours each. Also, in Bluepharma the production 
stops during weekends, so we didn’t considered them. These information lead us to the 
scheme in the Table 4: 
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Years Weeks per Year Days per Week Shifts per Day Hours per Shift 
1 50 5 2 or 3 8 
Table 4 - Available working time considered to estimate the equipment capacity. 
As we can see we considered 2 weeks of complete stop of the company. Plus, we made 
calculations for 2 and 3 shifts of operation.  
During this time, the machines need to stop working for several reasons: for 
maintenance, changing of the material, cleaning, product changing, etc. We call this the 
downtime of the machines. This downtime varies from machine to machine and 
depends also on the production planning. Nevertheless, the contact with the suppliers 
gave us important information to set a transversal downtime calculation for the coating 
equipment. 
Heating and 
Calibration 
Cooling down Cleaning Coils change 
per shift 
Maintenance 
per year 
90 min 90 min 45 min 30 min 2 days 
Table 5 - Considered downtime for the coating machines. This values result from the conversations 
with the suppliers. 
The downtime of the machines, in the Table 5, was considered the same for all machines 
because we had very similar answers from the different suppliers. Nevertheless, it was 
not always easy to get this type of information from the manufacturers. 
We applied these downtimes differently for 2 shift and 3 shift operation: 
 2 shift operation: Heating, cooling and cleaning happens every day. 
 3 shift operation: Heating happens in the beginning of the week, and cooling 
and cleaning in the end of the working week. 
The equipment is prepared to work continuously. If we assume they work 24 hours per 
day, it is only necessary to heat when the production starts (in the beginning of the 
week) and to cool in the end of the journey. We also considered that for a 3 shift 
operation, only one product is produced per week. Product change just happens from 
one week to the next. That’s why it is only necessary to clean the machine in the end of 
the journey. On the contrary, for the 2 shift operation system there is the need to heat 
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and cool the machine every day and also to clean it, because it is not an acceptable 
practice in the pharmaceutical industry not to clean the equipment when there is a 
planned interruption of the production. 
Translating this to a mathematical equation we have for a 2 shift operation: 
𝐷𝑇(2) = (𝐻𝑡 + 𝐶𝐿𝑡 + 𝐶𝑡) ∗ 𝑁𝑑 + (𝐶𝐻𝑡 ∗ 𝑁𝑑 ∗ 𝑁𝑠ℎ) + 𝑀 
Eq. 4 
While for a 3 shift operation we have: 
𝐷𝑇(3) = (𝐻𝑡 + 𝐶𝐿𝑡 + 𝐶𝑡) ∗ 𝑁𝑤 + (𝐶𝐻𝑡 ∗ 𝑁𝑑 ∗ 𝑁𝑠ℎ) + 𝑀 
Eq. 5 
In Eq. 4 and Eq. 5  𝐻𝑡 is the heating time, 𝐶𝐿𝑡  the cleaning time, 𝐶𝑡 the cooling time, 
𝐶𝐻𝑡 the time for coil changes, 𝑁𝑑 the total number of working days, 𝑁𝑤 the total 
number of working weeks, 𝑁𝑠ℎ the number of shifts per day and 𝑀 the maintenance 
time of the machine. 
Overall Equipment Effectiveness (OEE) 
In order to have more accurate and realistic results, we decided to use one of the most 
known efficiency indicators in the manufacturing industries, namely in the pharma 
industry. The Overall Equipment Effectiveness (OEE) can be defined as a best practice 
measurement that shows the truly productive time of the planned production.[24] 
 
Figure 9 - Illustration of the Overall Equipment Effectiveness (OEE) logics. 
As we can see in the Figure 9 there are 3 concepts that define OEE. These concepts are 
rates and can be defined as: 
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𝐴𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑇𝑖𝑚𝑒
𝑃𝑙𝑎𝑛𝑛𝑒𝑑 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑇𝑖𝑚𝑒
 
Eq. 6 
  
𝑃𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒 =
𝑃𝑎𝑟𝑡𝑠 𝑃𝑟𝑜𝑑𝑢𝑐𝑒𝑑 ∗  𝐼𝑑𝑒𝑎𝑙 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦
𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 
 
Eq. 7 
 
𝑄𝑢𝑎𝑙𝑖𝑡𝑦 =
𝐺𝑜𝑜𝑑 𝑃𝑎𝑟𝑡𝑠
𝑃𝑎𝑟𝑡𝑠 𝑃𝑟𝑜𝑑𝑢𝑐𝑒𝑑
 
Eq. 8 
 
The availability takes into account the planned downtime of the machines, as we have 
seen before in Table 5. The Performance measures the behavior of the machine during 
the available operating time, and can be seen as a confrontation between the 
theoretical output and the real output. For example, if the velocity of the machine is 
supposed to be 10m/s and the corresponding output 100 m2, but the final result it’s just 
50 m2 of output, this means that the medium velocity during the operating time was just 
5m/s, and so, the performance was just 50% of the expected. According with the 
suppliers’ information, this happens mostly due to unplanned stops, short stops or lack 
of material for example. The Quality factor it’s given by the number of good parts (or 
good product). In any industrial process there is always defects in the production and it 
also affects the final efficiency. 
In the Table 6 we can see the major loss causes for each OEE factor. 
OEE Availability Performance Quality 
Major Loss 
Causes 
Planned maintenance, 
training, cleaning, changeover 
Lower speed, short stops, 
underutilization 
Startup losses, 
rejects, rework 
Table 6 - Principal causes that affect directly the OEE. 
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The OEE is a dynamic tool, and it should be used “on-time” in order to understand where 
a manufacturing process can be improved and how. In what concerns this project, it’s 
easy to understand that we cannot know how many short stops or how many reject 
products we will have. Nevertheless, it is possible, assuming some hypothesis, to have 
an acceptable OEE model, and this was what we’ve done. 
It’s good to remind that we are estimating the full capacity of the machines for one year 
of production. Has we have seen before, we considered 50 weeks of 5 days as the 
available time, and 2 and 3 shifts per day. Also as showed before, we know the habitual 
downtimes for this type of machines and we know how to calculate it. So, knowing the 
Downtime and the Available Time, we can easily calculate the Availability (Eq. 6). 
𝐴𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑇𝑖𝑚𝑒
𝑃𝑙𝑎𝑛𝑛𝑒𝑑 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑇𝑖𝑚𝑒
 
In the Table 7 it’s possible to see the different values of the OEE ant its factors for the 
different number of shifts. 
Column1 Availability Performance Quality OEE 
2 Shift Operation 69,1% 75,0% 95,0% 49,24% 
3 Shift Operation 89,8% 75,0% 95,0% 64,00% 
Table 7 - Considered values for each OEE factor and the respective OEE result, for an operation of 2 
and 3 shifts. 
As we can notice, the OEE it’s approx. 20% lower for a 2 shift operation due to the fact, 
that the number of planned stops is higher if the equipment doesn’t work continuously 
during the entire week. 
The values of the Performance and Quality were assumed by us. As we said, it’s not 
possible to know them at this point. Thereby, we asked directly every supplier about the 
OEE performance and quality rates for their machines, and almost all answers were 
those values or very near them. The maximum value given by one of the suppliers was 
80%, while the minimum was 65%. 
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With the OEE estimated for every machine, we were then in conditions to estimate the 
capacity of each equipment, by applying the following formula: 
𝐶(𝑚2) = 𝑇𝑖𝑚𝑒 (𝑚𝑖𝑛) ∗ 𝑂𝐸𝐸 ∗ 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦(𝑚/𝑚𝑖𝑛) ∗ 𝑊𝑒𝑏 𝑊𝑖𝑑𝑡ℎ(𝑚) 
Eq. 9 
4.4.2 Primary Packaging Equipment 
As we have seen in the second chapter, the primary packaging equipment combine both 
production and packaging processes: 
 Web Converting (Production): the coated film is cut into small strips with de 
desired size. 
 Primary Packaging (Packaging): the small strips are packed into a small pouch 
by hot sealing. 
The limiting step of these manufacturing phase is the primary packaging of each 
individual film strip into a pouch.  It is the size and the material of the pouch that has 
the most important impact on the final output of the equipment. This happens because 
OTFs don’t vary very much in terms of size, and once they are small, size variations don’t 
significantly affect the web converting process velocity. On the contrary, variations in 
the pouch size can have a significant impact on the output of the machine. Also the 
pouch material has a very important influence. For example, if a certain material takes 
more time to seal than other, we’ll have a lower output.  
At this stage of the project the primary packaging material is not known nor the size of 
the pouches.  
Thereby, we used the claimed capacity of each supplier to estimate the maximum 
capacity for each equipment. Contrary to the coating machines where the output is 
given by the velocity that in turns depends on the formulation, in this case it is given by 
the maximum number of pouches per minute. 
Taking all this into account and considering the principles referred before the following 
formula was applied for this estimation: 
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𝐶(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑂𝑇𝐹𝑠) = 𝑇(min) ∗ 𝑂𝐸𝐸 ∗ 𝑁𝑜𝑡𝑓(
𝑂𝑇𝐹
𝑚𝑖𝑛
) ∗ 𝑁𝑙 
Eq. 10 
The capacity 𝐶 is then equal to the multiplication of the working time 𝑇 by the 𝑂𝐸𝐸, the 
number of strips, 𝑁𝑜𝑡𝑓, produced per minute in each lane and the number lanes 𝑁𝑙. As 
we have seen, machines can have one to several production lanes embedded. Once we 
are estimating the maximum capacity, we considered the total number of lanes of each 
equipment. 
 
4.5 Outline Design of the Manufacturing Facility  
One of the challenges of this project was to outline the manufacturing facility for OTF 
production in terms of space, building requirements and overall investment needed.  
This projection should include laboratorial, pilot and commercial scale equipment, in 
order to gather all phases of the product development, since the lab until the 
commercial scale manufacturing. 
The first step consisted in searching information regarding other facilities used to the 
same purpose. We then collect information from inside the company that lead us to a 
first design that was several times improved until we reach the final draw that is 
presented in this dissertation. 
 
4.6 Bluepharma Forecast and Road-Map 
At this point we already could answer to these two questions: what we need? How does 
it work? But to answer to the question, “when do we need it?” we have to look to the 
company’ sales forecast. 
First of all it’s important to say that the forecasts were provided by Bluepharma. As we 
will see in the confrontation between the capacities estimated and the sales forecast, 
these sales predictions are represented in number of OTFs per year and they go until 
the year of 2025. 
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But as we’ve seen, we can only consider the total number of OTFs as the unit of 
calculation for the primary packaging equipment. The production and packaging 
processes are independent, and in the case of the coating process the output is given in 
square meters. Thereby, we must convert the total number of strips of each product in 
area of film: 
𝐴(𝑎𝑟𝑒𝑎) = 𝑁(𝑂𝑇𝐹𝑠) ∗ 𝑆𝑡𝑟𝑖𝑝 𝐴𝑟𝑒𝑎 
Eq. 11 
𝑇𝑜𝑡𝑎𝑙 A(𝑎𝑟𝑒𝑎) = 𝛴(𝑁(𝑂𝑇𝐹𝑠) ∗ 𝑂𝑇𝐹 𝐴𝑟𝑒𝑎) + 20% 
Eq. 12 
It’s easy to understand that multiplying the area of the strip by the number of strips we’ll 
have the area of film they represent. However, and as demonstrated in the last formula, 
we should consider at least 20% more of area. This is explained by the fact that there is 
a significant product loss (waste) when it passes from the coating to converting machine. 
In other words, not all the film that is produced ends inside a pouch ready to use. Due 
to this reason, we should produce more area of film in order to compensate these losses. 
So, following this method we obtained the forecast in the number of strips and also the 
area of film needed. Therefore, we were able to compare both coating and primary 
packaging machines capacities with Bluepharma sales expectation and draw a road-map 
and the corresponding milestones for the next ten years. 
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5 Results and Discussion 
In this chapter we will describe and analyze the results of the prospection that was 
made. 
For confidentiality reasons we will not use the names of any of the companies contacted 
nor the equipment models that we’ve analyzed. Instead, the following letter system will 
be used: 
 The first letter describes the type of equipment: “M” – for mixing equipment; 
“C” – for coating equipment; “P”- for primary packaging equipment; 
 The second Letter tells the supplier, and can goes from “A” to “B”, “C”, “D”, “E”, 
etc. 
 The last letter describe the scale of the equipment: L – for Lab, “P” – for Pilot and 
“I” – for Industrial scale. If a supplier has more than one equipment for a certain 
scale then the last letter must have a number next to it (ex: P1 for pilot 
equipment number one, P2 for pilot equipment number 2) 
Let’s use an example. “MD-P2”: mixing equipment, from supplier D, pilot scale, model 
2.  
 
5.1 Identification of CMOs and Possible Suppliers 
This first stage comprised the identification of possible equipment suppliers and the 
Contract Manufacturing Organizations (CMOs) in the market for benchmarking 
purposes. This is a particularly important step. On one hand suppliers can give us the 
necessary input on equipment specifications and prices, on the other CMOs are a good 
barometer not only to classify the possible suppliers, but also to understand how the 
different market regions are responding to this new kind of dosage form. 
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Figure 10 – Geographical distribution of the OTFs contract manufacturers organizations (CMOs) and 
the identified equipment suppliers. 
Figure 10 shows the distribution of Oral Thin Films CMOs and Equipment Suppliers, for 
Mixing, Coating and Primary Packaging. As we can notice, most of the equipment 
manufacturers are established in Europe while the majority of CMOs are in the United 
States of America. In fact, Europe (mainly Germany, as we will see) is the region with the 
biggest concentration of machinery and equipment companies.  
It’s almost common sense that Germany is known by their robust machinery, and the 
pharma equipment is not an exception. It’s is estimated that 1 in each 4 pharma 
machines are made in Germany or by German companies [25]. Also, the basis for 
innovation in the most prominent players in the pharma packaging equipment is set up 
in the growing need of solutions for novel drug delivery systems, like OTFs [26]. 
On the other hand most of the OTF manufacturers are in the USA. The first reason that 
can explain this is that the USA is where the Headquarters of the major pharma 
companies are located [27]. The other reasons is due to the fact that OTF products are 
more accepted by the patients in the USA than in Europe, because this is a technology 
that was first introduced there and also because both OTC and Rx OTF were first 
launched in the USA [21], [28].  
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As we’ve seen before, from the market search 21 possible equipment suppliers were 
identified, 7 for each type of equipment: Mixing, Coating and Primary Packaging.  
 
5.2 The Procurement Process 
5.2.1 Mixing Equipment 
 
Table 8 - Resume of the procurement process for the mixing equipment. 
Table 8 resumes the selection of the possible suppliers of the mixing equipment. Five 
potential suppliers were selected (out of seven) which presented a total of 23 different 
types of machines.  
As we can see, we asked for equipment in each of the three phases (lab, pilot and 
industrial). This only happens for this type of equipment because Bluepharma already 
has specific lab scale equipment for coating and primary packaging. .  
During the course of this work and in result of the procurement process, a lab mixing 
equipment with the features identified as critical for OTF manufacturing process was 
acquired and is operational. 
Mixing Supplier A B C D E F G
Country Germany UK Germany Switzerland Germany USA USA
Equipment for Pharma 
Industry
Yes Yes Yes Yes Yes Yes Yes
Possible Matching 
Equipment
Yes Not Clear Yes Yes Yes Not Clear Not Clear
Selected for First Round Yes Yes Yes Yes Yes Yes Yes
Contact Yes Yes Yes Yes Yes Yes Yes
Answer Positive Positive Positive Positive Positive No answer No answer
Type of Contact
Local 
Representative
Local 
Representative
Local 
Representative
Direct Direct
Presentation of Formal 
Quotations
Yes Yes Yes Yes Yes
Lab Scale equipment 3 1 1 2 -
Pilot Scale equipment 1 1 1 1 1
Industrial Scale 
equipment
3 - 3 2 3
Final Group of Suppliers Yes Yes Yes Yes Yes No No
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5.2.2 Coating Equipment 
 
Table 9 - Resume of the procurement process for the coating equipment. 
In what concerns to coating equipment seven different companies were identified. In 
the first step we eliminated one of these possible suppliers, due to the fact that we 
couldn’t find enough information about the company and because the only equipment 
sold by this company is also supplied by another company that was selected for contact. 
Another company was discarded because they only operate in the Scandinavian region.  
Finally, the last company excluded from the final list of suppliers never provided an 
official budget quotation or any technical information although several emails were 
exchanged.   
 
 
 
 
 
 
Coating Supplier A B C D E F G
Country Germany Germany Switzerland Germany USA USA Denmark
Equipment for Pharma 
Industry
Yes Yes Yes Yes Not Clear Yes Yes
Coating Machines for 
OTFs
Yes Yes Yes Yes Not Clear Not Clear Not Clear
Selected for First Round Yes Yes Yes Yes No Yes Yes
Contact Yes Yes Yes Yes Yes Yes
Answer Positive Positive Positive Positive Positive Negative
Type of Contact Direct Direct
Local 
Representative
Direct Direct
Presentation of Formal 
Quotations
Yes Yes Yes Yes No
Pilot Scale equipment 2 1 1 1 -
Industrial Scale 
equipment
2 1 1 - -
Final Group of Suppliers Yes Yes Yes Yes No No No
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5.2.3 Primary Packaging Equipment 
 
Table 10 - Resume of the procurement process for primary packaging equipment. 
Finally the web converting and primary packaging equipment, in the Table 10. Only one 
company was excluded after the preliminary analysis because it was not possible to find 
any solid information about equipment or guaranties of experience and quality. The 
contrary happened with another supplier, a well-known company in pharma industry 
with high experience in the packaging field. We even had a face-to-face meeting with 
the local representative, but we never received any official proposal. The same occurred 
with one last company, with the difference that from this company we received some 
preliminary information and indicative prices, but never an official quotation.  
5.2.4 General Analysis  
All this process was a very intense and with a lot of exchanged information, as it can be 
seen in the Table 11. 
Emails exchanged Phone calls Meetings 
Equipment models  
analyzed 
> 300 >30 6 39 
 
Table 11- Some numbers that describe the intense contact with equipment suppliers and the number 
of machines analyzed.  
Primary Packaging 
Suppliers
A B C D E F G
Country USA Italy Germany Germany USA Germany Índia
Equipment for Pharma 
Industry
Yes Yes Yes Yes Yes Yes Not Clear
Primary Packaging 
Machines for OTFs
Yes Yes Yes Yes Not Clear Yes Not Clear
Selected for First Round Yes Yes Yes Yes Yes Yes No
Contact Yes Yes Yes Yes Yes Yes
Answer Positive Positive Positive Positive Positive Positive
Type of Contact Direct Direct Direct Direct Direct
Local 
Representative
Presentation of Formal 
Quotations
Yes Yes Yes Yes No No
Pilot Scale equipment 1 1 1 1 - -
Industrial Scale 
equipment
1 1 1 1 - -
Final Group of Suppliers Yes Yes Yes Yes No No No
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In the next two charts (Graphic 1 and Graphic 2) it is possible to compare the initial 
number of identified companies and the final selection as well as the geographic 
distribution of the selected companies by country.  
 
Graphic 1 - Comparison between first identified equipment manufacturers and the selected. 
 
Graphic 2 - Geographical distribution of the selected suppliers, by country. 
Graphic 3 shows the number of equipment’s analyzed by type and by scale. Analyzing 
the graph it is possible to observe that there is a higher variety of suppliers of mixing 
equipment than coating and primary packaging equipment. This is expected considering 
that this type of equipment can be used in several types of dosage forms, while the 
coating and primary packaging equipment is limited to the manufacture of OTFs or 
transdermal patches. 
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Graphic 3 - Number of different models analyzed by type and by scale. 
In conclusion, 62% of the first identified suppliers were selected for the final group of 
suppliers, 9% were eliminated in the preliminary analysis and 29% were not considered 
because the response was negative or because proposals were not sent to Bluepharma. 
Thereby we truly believe this was a task performed successfully.  
 
5.3 Identification of the critical requisites 
The machines’ specifications were carefully analyzed in order to identify the ones with 
higher impact on the manufacturing process. It’s important to mention that the 
equipment analyzed is very complex, with hundreds of technical components. The main 
objective of this project was not to make a complete analysis and comparison but to 
identify the critical ones. 
5.3.1 Mixing Equipment 
In the procurement process for the mixing equipment the main objective was to find 
solutions that could guarantee a proper scale-up (e.g. equipment working with the same 
process in all scales). Furthermore, there was already an advanced know-how in 
Bluepharma about the main difficulties of the mixing process which helped the work 
being performed.  
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Regardless the formulation composition, it is mandatory to achieve a perfectly 
homogeneous mixture. This means a mixture without bubbles or lumps and with a 
homogeneous distribution of the drug(s) substance(s). The existence of any of those 
problems can seriously compromise the coating process. 
The equipment recommended for the mixing process of OTFs corresponds to highly 
advance processing units, developed for the production of emulsions and suspensions 
mainly to the pharmaceutical industry. Besides the typical mixing features, like agitation 
for example, they allow to work with high pressures or vacuum and to regulate the 
temperature, among several other functions. 
In Figure 11 it’s possible to see the outlook of a typical processing unit used in the 
preparation of OTFs. 
 
Figure 11 – Example of a mixing equipment with an anchor agitator. (Image from supplier M.A). 
Figure 12 shows a schematic representation of a mixing equipment that will be useful to 
understand the discussion.  
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Figure 12 - Schematic representation of a mixing equipment used for the production of OTFs.  Legend 
on the left side. (Image from supplier M.B) 
The different models analyzed have a very large range of volumes, from dozens of liters 
to thousands. The choice of the right volume and the number of equipment and vessels 
to acquire, depend on the volumes of OTFs that are projected to be produced and also 
on the number of different products. 
Each company contacted offer equipment for both pilot and industrial scale. We have 
requested the following volumes to the suppliers according with the scale: 
 Pilot Scale: 50 Liters. 
 Industrial Scale: 500, 1000 and 2000L. 
 
Regarding the lab scale the major concern was the minimum volume because in the 
beginning of the R&D of new formulations it is very important to work with very small 
volumes to be as cost-effective as possible.  
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Agitation 
There are various types of agitators in the market, such as propeller, anchor or magnetic 
agitators. Our demand focus was on the anchor agitators (Figure 13) that are anchor 
shaped and their blades are very close to the walls and to the bottom of the vessel. They 
work in low to medium velocities and are recommended for medium to high viscosity 
solutions or emulsions and for laminar fluids. This can be explained looking to the 
Reynold’s Number: 
𝑅𝑒 =
𝑖𝑛𝑒𝑟𝑡𝑖𝑎𝑙𝑓𝑜𝑟𝑐𝑒𝑠
𝑣𝑖𝑠𝑐𝑜𝑢𝑠𝑓𝑜𝑟𝑐𝑒𝑠
 
Eq. 13 
The number of Reynolds is lower when the viscosity is higher, and in this case near-walls 
agitators are recommended to shear the mixture [29].  
 
Figure 13 -Example of an anchor agitator for laboratory scale. It is also visible the wall scrapers in 
white. (Image from supplier M.A). 
However, for higher volumes the anchor agitators do not show a high performance, 
because the center zone experience little movement resulting in a non-efficient mixing 
[29]. Thereby, pilot and industrial equipment present more complex agitators in order 
to surpass this limitation, like agitators with both internal and external agitation and 
temperature controlled systems.  
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Figure 14 - Detail of an anchor agitator for pilot scale mixing. Besides the external anchor, it's possible 
to notice the internal counter rotating agitator. (Image from supplier M.A). 
As the Figure 14 shows, the anchor works as an external agitator that moves close to the 
walls and the bottom of the vessel, while the counter rotation agitator (or blade) is 
placed in the center of the vessel and rotates in the opposite direction of the anchor. 
The counter rotating is normally vertical and has several paddles along it. This 
technology is used due to the high vessel volumes, to ensure a constant and uniform 
agitation not only in the borders but also in the center of the vessel. 
Another important feature to mention are the wall scrappers (indicated in the Figure 
13). These pieces, normally made of PTFE, scrap the walls and the bottom of the vessel, 
what ensure that no agglomerates stay glued to the borders of the vessel. 
Homogenization 
As referred before, one of the most important goal to achieve in the formulation of OTFs 
is a truly homogeneous mixture. The production step (coating) comprehends the 
spreading of the solution on a substrate. If the solution has solid agglomerates or air 
bubbles, for example, an entire batch can be compromised because the resulting film 
will not comply with the specifications. To achieve perfect homogenization, dispersion 
equipment (or homogenizers) are commonly used. The dispersion process can be 
defined as the mixing of at least two substances that don’t dissolve in each other, hardly 
react with each other  or don’t chemically react with each other [30].  
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However, and as all the suppliers have explained, these tools are able to mix any mixture 
and with better results than a simple agitator, because the mixture it’s dispersed at very 
high velocities. Nevertheless it’s important to say that it doesn’t make the agitator 
dispensable. The agitator guarantees the uniformity of the mixture inside the vessel and 
pushes it in the direction of the homogenizer, mainly in bigger vessels.  
 
Figure 15 – Dispersion head. a) Representation of what happens in the dispersion head, showing the 
smaller particles being expelled at high velocity. b) Representation of the rotor stator system. The 
rotor moves at high velocity sucking the mixture and then expelling it through the slots in in an in the 
stator, making the mixture to spilt into disperse phase. 
These homogenizers have a principal component that is the dispersion head, which 
works according to the rotor-stator principle, as demonstrated in the Figure 15. The 
rotor operates at very high velocities creating a very powerful axial suction force that 
sucks the mixture into the dispersion head, where the rotor rotates at very high velocity 
forcing the mixture through the stator slots. The mixture is submitted to very high shear 
forces through those slots being spliced. There are three main factors that characterize 
these instruments: 
 Range of Velocities: to create the necessary high shear forces, the rotor has to 
reach very high velocities, in the order of thousands revolutions per minute 
(RPM). Nevertheless, very high velocities can damage more sensitive mixtures, 
for example, mixtures containing some kinds of polymers [31]. In this case, it’s 
important to have special attention to the minimum velocities of the 
homogenizers.  
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 Dispersion head: for each equipment there are several different heads available, 
with different shapes and different slot sizes. The selection of a suitable 
dispersion head should take into account the type of the formulation in order to 
achieve maximum homogenization. 
 Mode of operation: there are two different types of homogenizers, the batch 
and the in-line homogenizers. The first ones are individual tools, normally with 
the format of a magic wand for kitchen and are placed in an overhead position 
on the top of the vessel.  In the Figure 16 these two operation modes are 
represented. 
 
Figure 16 - Different operation modes of homogenizers. a) Shows a batch disperser placed on top of 
the vessel. b) In-line homogenizer, connected to the bottom of the vessel. It creates an external 
circulation of the mixture. 
While in the batch homogenizer the disperser head is inside of the vessel and the 
dispersion happens locally, in the case of the in-line dispersers the disperser heads are 
located outside the vessel (normally on the bottom or connected to it) and create a 
circulation circuit (Figure 16). These last ones are more effective, once they ensure that 
all the mixture passes by the circuit of dispersion several times. This is particularly 
relevant for higher volumes (e.g. pilot scale and industrial scale). For our project, we 
considered the batch dispersers only for laboratory equipment due to the higher 
volumes of pilot and commercial scale. However, some laboratory solutions present also 
in-line homogenizers, what is an advantage in terms of scale-up. Although, to use this 
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type of homogenizer higher volumes are needed when compared with the batch 
laboratory homogenizers, which is a disadvantage once we seek the minimum volume 
possible for this scale.  
Vacuum 
Another critical aspect of the formulation process is to avoid aeration, i.e. formation of 
air bubbles inside the mixture. During a mixing process it is frequent the formation of 
bubbles or foam. 
To avoid this, manufacturers of mixing equipment offer optional accessories that ensure 
that the mixing process is made under vacuum conditions. These accessories are 
normally vacuum pumps, which are connected to the vessel through an inlet that is 
sealed and when operating can create vacuum inside by sucking the air inside of the 
vessel. 
Nevertheless, other factors can help to avoid aeration. For example, if a batch disperser 
is used, the dispersion head should not be placed closed to the surface of the mixture in 
order to avoid turbulence, which can promote the formation of bubbles or foam. In any 
case, an in-line disperser is always a better option, because the recirculation system 
created also helps to eliminate the air entrapped in the mixture.  Also it is possible to 
add the solid ingredients (like powders) directly in the in-line homogenizer so it passes 
in the rotor-stator before it enters in the mixing vessel, which avoid the formation of 
lumps and air bubbles.  
Temperature Control 
The control of the temperature in a mixing process is very important. Depending on the 
formulation, heat may be necessary. The agitation and homogenizing tools, for example, 
can create heat that affect the stability of the mixture. The necessity to keep the mixture 
at high or low temperatures depends on the composition of the formulation. However 
it is crucial to have the temperature controlled at all time. The presence of unwanted 
moisture can compromise the OTF mechanical properties, plus it can be necessary to 
change process temperature to improve or reduce the viscosity of the mixture [15]. Also, 
drug substances are often very sensitive to temperature, being necessary to control this 
parameter in order to not affect it [18]. 
RESULTS AND DISCUSSION 
52 
 
In the pilot and industrial scale equipment analyzed, the vessels have a double wall 
jacket and for heating the mixture, compressed air and steam are introduced in the wall 
jacket. On the other side, to cool down the mixture, cold water is introduced in the wall 
jacket.   
Specifications of the Quoted Equipment 
The Table 12 and Table 13 resume the specifications of the different quoted equipment.  
Type Mixing Equipment (M) 
Supplier A B C D 
Model L1 L2 L3 L1 L1 L1 L2 
Code M.A-L1 M.A-L2 M.A-L3 M.B-L1 M.C-L1 M.D-L1 M.D-L2 
Maximum 
Volume (L) 
1 2 2 - 3 1 2 
Minimum 
Volume (L) 
0,5 0,8 0,8 - 0,75 0,45 1,1 
Máx. 
Viscosity 
(mPas) 
100.000 150.000 150.000 - 50.000 50.000 50.000 
Agitator Anchor Anchor Anchor - Other* Anchor Anchor 
Wall 
Scrapers 
Yes Yes Yes - Yes Yes  Yes  
Agitator 
Speed (rpm) 
10 - 150 8 - 290 ndi - 30 - 150 10 - 400 10 - 400 
Homogenizer Batch Batch 
Batch/In-
line 
Batch/In-
line 
In-line Batch Batch 
Homogenizer 
Speed (rpm) 
 3.000 - 
25.000  
3.000 - 
25.000 
3.000 - 
25.000 / 
3.000 - 
26.000 
0 - 6.000 
3.000 - 
12.000 
500 - 
30.000 
500 - 
30.000 
Vacuum 
Pump  
Yes Yes Yes - Yes  Yes  Yes  
Temperature 
Control 
Yes Yes Yes - Yes Yes  Yes  
    ndi: not delivered information 
 
* patented and registered technology of the supplier that cannot be revealed due to 
confidential reasons 
Table 12 - Specifications of the quoted mixing laboratory equipment. 
On Table 13 it is possible to find the specification of the laboratory equipment. In what 
concerns the volume, our major concern was the minimum working volume, because 
the in the R&D phase of new OTFs formulations it is normal to work with very small 
volumes in order to reduce costs. Only two can of the models work with 0,5 Liters or 
less, and these volumes are closer to Bluepharma’s needs for this scale. 
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The supplier of equipment M.B-L1 just sent data regarding the homogenizer 
specifications. This happened because this equipment corresponds to a homogenizer 
only.  Supplier B is known for its homogenizers and claims that, in certain cases, they can 
exclude the necessity of the agitator and that they can work with volumes in the order 
of 1 mL. Thereby we decided to consider this supplier just for laboratory equipment, 
even though it does not present any of the other features. 
Besides the M.B-L1 and M.C-L1 models, all the other options present an anchor agitator. 
This information agrees with what was referred before, that this type of agitators are 
recommended for medium to high viscosities, which is the case of OTFs formulations 
[29]. Nevertheless, the M.C-L1 has a patented technology that was designed for working 
with high viscosities and the supplier “C” claims that it ensures far better results than a 
typical anchor agitator. 
Looking to the type of homogenizer we can see that there are models with in-line 
homogenizers for lab scale. This is an important thing to consider, because at pilot and 
industrial scale, most of the equipment uses this technology. In addition to ensure a 
better homogenization, if we use the same process in all scales, the scale up process will 
have a higher probability to have success. 
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Type Mixing Equipment (M) 
Supplier A C D E 
Equipment P1 P1 P1 P1 
Code M.A-P1 M.C-P1 M.D-P1 M.E-P1 
Maximum Volume 
(L) 
50 50 50 60 
Minimum Volume (L) ndi 13 ndi 8 
Max. Viscosity 
(mPas) 
100.000 50.000 50.000 ndi 
Agitator 
Anchor + Counter 
rotating blade 
Other* Anchor 
Anchor + 
Counter rotating 
blade 
Wall Scrapers Yes yes Yes Yes 
Agitator Speed (rpm) 22 - 66 24 to 120 ndi ndi 
Homogenizer In-line In-line Batch/In-line In-line 
Homogenizer Speed 
(rpm) 
 3.000  600 - 4.800 
Max. 3.000/ 
10.000 
600 -3000 
Homogenizer 
Recirculation 
 External  
Internal / 
External 
ndi 
Internal / 
External 
Vacuum Pump  Yes Yes Yes Yes 
Temperature Control 
Double jacket 
System 
Double Jacket 
System 
Double Jacket 
System 
Double Jacket 
System 
CIP Yes Yes Yes Yes 
ATEX (option) Yes Yes Yes Yes 
 ndi: not delivered information 
* patented and registered technology of the supplier that cannot be revealed due to confidential 
reasons 
Table 13 - Specifications of the quoted mixing pilot equipment. 
For the pilot equipment the target volume was 50 liters but the information regarding 
the minimum working volume is also important. However only two suppliers provided 
that information and as it can be seen in the Table 13, the M.E-P1 presents the lowest 
useful volume, 8 liters.  
Finally, all the models allow the regulation of temperature, vacuum, clean-in-place (CIP) 
and ATEX configuration. ATEX are the European guidelines and directives to work with 
Explosive Atmospheres [32]. In many industries, like pharma, there are processes were, 
for example, inflammable or explosive materials are handled. In this case the equipment 
must be configured in order to meet those guidelines. 
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For industrial scale the models are exactly the same presented for pilot scale, the 
specifications are practically the same and the only major difference is the higher 
working volume. Using the same models will reduce the probability to have problems in 
the scale-up of the production.  
Thereby, the suppliers “A”, “C” and “E” presented proposals for 500L, 1000L and 2000L 
capacities, while the supplier “D” only sent us quotes for 500L and 1000L. 
 
5.3.2 Coating Equipment 
As referred in the introduction part, coating machines are responsible for transforming 
the liquid mixture into a solid thin film. The process consists in applying one or more 
coverings (laminates) in a substrate (release liner). In the Figure 17 it’s possible to see 
an industrial coating machine for the production of OTFs. These machines are normally 
very long due to the dryer’s big length.  
 
Figure 17- Example of an industrial scale coating machine. 
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The Figure 18 shows a scheme of the coating process for OTFs, as explained before.  In 
the end the coated films instead of being winded in one roll, it’s is first cut in two and 
winded into two smaller rolls. As we’ll see further this due to an optional feature called 
slitting station that allow us to have two independent coated rolls with a smaller web 
width. 
Web Width 
The web width can be defined as the maximum release liner (web) width that is accepted 
by the coating machine. Normally the machines don’t have a fixed width, instead they 
have defined a maximum value. Pilot scale machines have normally a shorter web width 
than the industrial ones, the main difference is in the length. It is easy to understand 
that the web width as well as the web length are directly related with the machine 
output. 
Dryer 
The dryer plays a very important role in the coating process. These dryers are very 
complex systems and the process has to be perfectly adjusted to the mixture 
Figure 18 - Scheme of the coating machine path since the uncoated web to the final coated film. 
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composition in order to ensure a final OTF with the desired properties (plasticity, 
elasticity). The film has to be dried at a constant velocity and the film cannot be inside 
of it more than the calculated time, otherwise it may become brittle.  
It’s also important to refer that the dryers normally come in modules, this means that it 
is possible to add more modules depending on the capacity that we will need (each 
module increases the dryer length). This concept is present in the industrial scale 
machines, but not at pilot scale.  
The length of the dryer is probably the most critical aspect of these machines since a 
dryer with a higher length is synonymous of a higher output of the machine. It’s easier 
to understand if we look to what happens in the machine: the web (release liner) moves 
slowly in the dryer direction, before it enters the dryer, the mixture is spread in the 
release liner a fixed thickness and after that, it enters into the dryer. The velocity which 
the web moves it’s determined by the time that the mixture has to stay inside the dryer 
in order to turn to the solid state. So, if we have a small dryer, the web will move very 
slowly and on the contrary if we have a longer dryer the web can run at a higher velocity. 
In any of those cases, the web will be the exactly same time inside the dryer, but the 
velocity it runs will be different.  
There are several drying techniques, like infrared, UV or microwave radiation, by contact 
eating or by natural air contact, for example. But in case of OTFs manufacturing, the 
method used by all the suppliers selected and their equipment is drying by hot air. This 
technique is used because it does not have some of the problems of other techniques:  
a) radiation techniques  may modify the OTF properties; 
b) heating by contact can damage the structure of the coated film due to the very 
small thickness it presents.  
Thereby, drying by hot air allows a uniform distribution of the heat around the film 
carrier at all moments, due to the convection current originated. Plus, it enables a slow 
and steady drying, which is the recommended procedure. If the drying process is too 
fast, the surface and bottom of the film will dry much before the middle part and the 
solvents can become cloistered inside, creating crusts in the film. 
Dimensions 
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The dimensions of the equipment (length, height and width) are important to make an 
estimation of the area required for the manufacturing facility. 
Application System 
The Application System (or coating heads) can be described as the machine feature 
responsible to coat the release liner with the mixture. These components are very 
precise and can ensure a wet thickness of micrometers. There are several types of 
coating heads and they are related with the material that is being produced. In the case 
of OTFs, the most common systems are the Knife Coater, the Slot Die and the Reverse 
Roll, however other possibilities may be considered.  
 
Figure 19 - Representation of three different coating systems: a) Knife Coater, b) Slot Die and c) 
Reverse Roll. 
In the Figure 19, the green layer represents the liner and the mixture is represented in 
red. The different systems all release the mixture at a constant rate and with a very 
precise thickness. The selection of the best options depends on the mixture properties, 
mainly its density, viscosity and composition. All suppliers selected equipment models 
appropriate for the production of OTFs 
Release Liner 
There are several options on the market of release liners. In the OTF manufacturing 
process, it is mandatory that this product fill all the quality requisites required by the 
authorities, namely the FDA (for the US market) and the EMA (for the European market). 
Release liners for OTFs production are normally made of a polymeric film or paper 
substrate that may be coated with silicone. 
The release liners play a crucial role in the manufacturing process of OTFs besides being 
the substrate where the mixture is spread. These liners provide extra strength to the 
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film, helping to maintain its integrity and surpass all the stresses during the 
manufacturing process [33]. Before the packaging of the OTFs into individual pouches 
the release liner is peeled off releasing the film without damaging it. 
One of the tasks of this work was to find a suitable release liner fulfilling the US and 
European regulatory requirements and non-siliconized. Most of the release liners for 
pharma are siliconized in one or both sides but considering the BlueOS technology 
composition these release liners are not compatible. Nevertheless, it was possible to 
find a non-siliconized release liner, compliant with all the necessary requirements.  
Specifications of the Quoted Equipment 
We will now compare the different equipment models that we’ve received proposals. 
The specifications for each equipment received are displayed in Table 14 (pilot scale) 
and Table 15 (industrial scale). 
Type Coating Equipment (C ) 
Supplier A B C D 
Equipment P1 P2 P1 P1 P1 
Code C.A-P1 C.A-P2 C.B-P1 C.C-P1 C.D-P1 
Length (mm) 2216 2200 3000 4121 3200 
Width (mm) 646 1000 1250 1500 1000 
Height (mm) 600 1100 1850 1600 1900 
Area (m2) 1,4 2,2 3,8 6,2 3,2 
Weight 190 1100 ndi ndi 6000 
Max. Web Width 
(mm) 
155 250 400 350 130 
Useable Coating 
Width (mm) 
120 200 250 200 100 
Coating System Coating Knife Coating Knife Roll Coater Knife/Slot die 
Knife over 
roll/Slot Die 
Dryer Sections 2 3 3 2 3 
Dryer Length (mm) 1600 3400 1660 1876 1500 
Dryer Technology Hot Air Hot Air Hot Air Hot Air Hot Air 
Slitting Station 
(option) 
No Yes ndi Yes ndi 
Adaptable for TDDS  Yes Yes Yes Yes ndi 
  ndi: not delivered information 
Table 14 - Specifications of the coating equipment for pilot scale. 
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As we can see, all the models have a small dimension (between 1,4 m2 and 6,2 m2 )  and 
have a small web width. Also, the dryer lengths are between 1,5m and 2m for four of 
the five models. Just the equipment C.A-P2 has a higher dryer length. This happens 
because this is the only machine where the dryer makes a U pathway, almost duplicating 
the length of the dryer path.  
Type Coating Equipment (C ) 
Supplier A B C 
Equipment I1 I2 I1 I1 
Code C.A-I1 C.A-I2 C.B-I1 C.C-I1 
Length (mm) 4700 6300 14180 9700 
Width (mm) 2100 2600 5200 1500 
Height (mm) 2100 2100 6362 2300 
Area (m2) 9,9 16,4 73,7 14,6 
Weight 7000 8000 ndi 7000 
Max. Web Width 
(mm) 
460 460 600 480 
Useable Coating 
Width (mm) 
440 440 500 460 
Coating System Coating Knife Coating Knife Roll Coater Knife/Slot die 
Dryer Sections 2 4 3 4 
Dryer Length (mm) 4700 8500 9000 3810 
Dryer Technology Hot Air Hot Air Hot Air Hot Air 
Slitting Station 
(option) 
Yes Yes ndi Yes 
Adaptable for TDDS  Yes Yes No Yes 
 ndi: not delivered information 
Table 15 - Specifications of the coating equipment for commercial scale manufacturing. 
As expected, the commercial scale machines have a significant higher dimensions when 
compared with pilot equipment (ranging from 9,9 m2 to 73,7m2). However, just the 
equipment P.B-I1 presents a significantly higher area value. This is explained by the fact 
that this equipment is a two store complex-like unit, what makes the occupied area 
higher than if we just considered the machinery parts. But once we considered the 
layouts given by the suppliers for these calculations, we decided to consider the 
equipment as a whole. Looking to the Figure 20 it’s easier to understand this concept. 
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Figure 20 - A scheme of a coating equipment similar to the P.B-I1, a two store complex where the 
machine parts are inserted. 
In what concerns the web width, all the models present the same range of maximum 
accepted values – around 0,5m. The dryer lengths are considerable different, with two 
models presenting values above the 5m and the other two presenting almost the 
double. Nevertheless, it’s is important to say that all the suppliers informed us that it is 
possible to add more dryer modules, although we just considered the parameters of the 
proposal that were sent. 
5.3.3 Primary Packaging Equipment 
Web converting and Packaging machines convert the coated film into small individual 
strips (production process) and after that they ensure the packaging of the final films 
into individual pouches (packaging process). Like the coating machines we’ve seen 
before, this type of equipment is very complex.  
 
Figure 21 - Outlook of a pilot scale web converting and primary packaging machine (eq. P.D-P1). 
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Looking to the Figure 22 we can describe the web converting and primary packing 
processes by the following steps: 
 From the left to the right, the film roll is inserted in a coil of the machine and 
starts to be unwinded. Also, the packaging material roll is inserted in the 
machine.  
 The packaging material is dived in two lanes (one for the upper packaging 
material and other for the bottom packaging material) and then it passes 
through a web printing station and verification, where the batch number and 
shelf life is printed. 
 The OTF film enters in a slitting station where the film can be divided in several 
lanes of an appropriate width. See Figure 23. 
 
Figure 23 - Detail of a primary packaging machine. a) Initial coated film; b) the film divided in several 
lanes; c) packaging material. (image from supplier P.D). 
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 After that, a cutting station cuts the film (already divided in lanes) into small 
strips with the desired size to ensure the appropriate DS strength in the final 
dosage form. In parallel, the release liner is peeled off and rewinded.  
 At the same time the strips are dropped in the bottom packaging material web 
and the upper packaging material is immediately placed on top.  
 
Figure 24 - Detail of a primary packaging machine. The OTFs strips already cut on the top of the 
release liner are then trasfered to the bottom packaging material and closed with the upper packaging 
material. (image from supplier P.D). 
 These three layers (bottom packaging material, film strips and upper packaging 
material) go into the sealing station.  
 In this station, the pouches are created by a four side hot sealing. The number of 
pouches made in each sealing cycle depends on the pouch size. At this point the 
strips are closed in a four sealed pouch but the pouches are still connected to 
each other.  
 The web keeps moving until a cross cut station where they are cut into individual 
pouches.  
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 Finally, the products follow through a conveyor and pass by a reject station 
where the bad parts produced are removed aside. 
 It’s possible to see a machine working in the following link: 
https://www.youtube.com/watch?v=jHCu99ZXBxo 
Principle of Operation 
Primary Packaging equipment can work intermittently or continuously. In the 
continuous mode the system is already running, non-stop, while in the intermittent 
mode the system runs by constant cycles. Most of the machines run continuously, but 
there are some pilot scale machines that run intermittently.  
The main difference is that the intermittent machines are used for smaller scale 
productions, while in the continuous mode the aim is the manufacture of batches with 
higher number of OTFs [34]. 
Slitting Station 
When it comes to pilot scale manufacturing, normally the web width of the coating 
machines fits directly into the primary packaging machines. At industrial scale, the web 
width is higher and the web converting and primary packaging machines are not directly 
compatible. Thereby, the coated rolls have to be slit in smaller ones before. To do this 
there are normally three ways: 
 The coating machines have a slitting station at the end that divides the film into 
two rolls instead of one. 
 The web converting and packaging machines have a slitting station in the 
beginning, which divides the coated roll in two rolls. 
 By using an individual slitting equipment that only slits the rolls produced by the 
coating equipment. 
The slitting equipment it the most preferred one because it allows to divide a roll in 
more than two rolls with the desired size. Plus, it does not interfere with any of the 
manufacturing processes. The search for these type of equipment was not one of the 
objectives of this work.  
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Cutting System 
The cutting technique used for OTF production is the kiss cut. It consists on making an 
unique cut with the desired shape and size that only cuts the thin film but not the release 
liner. In this way, the film waste (i.e. the surrounding edges) it’s peeled off and the 
individual strips, with the defined size and shape,  stay on the top of the release liner 
until it is also peeled off and the strips transferred to the bottom packaging web 
material.  
Number of Lanes 
Pilot scale machines normally have one operating lane. As for the commercial scale 
equipment it is possible to work with more than one lane when they have a slitting statin 
in their beginning. Thus, the process can be optimized which results in a higher output. 
The different lanes run alongside at the same process velocity and the capacity of the 
machine is calculated multiplying one lane output by the number of working lanes. 
Printing and inspection features 
Web converting and packaging machines for OTFs offer various options for printing. It is 
possible to print not only the expiration date and the batch number, but also the 
description of the content. Also it is possible to print directly in the OTF strip. 
The inspection features assures that all the process is going well in real time, by 
examining, for example, if the strip is correctly placed in the middle of the pouch, if the 
sealing was correctly done or if there is any empty pouch. In case of any error the 
machine gives an alert and the product is automatically rejected.  
These features are chosen according to the production needs and although they do not 
slow down the machines’ output, they can increase the machine cost significantly. The 
Figure 25 shows a detail of an inspection toll inspecting the size of each OTF strip. 
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Figure 25 - Detail of an in real time inspection tool. In this case it measures the size of the strips in 
order to know if it was cut correctly (equipment from supplier P.A). 
Pouch size, pouch material and sealing time 
These three aspects are the most relevant to determine the output of these machines. 
As referred before, there are two principal processes that occurs in these machines. The 
conversion of the inserted film roll into individual OTFs and then the primary packaging 
of those strips inside a pouch. These processes have to be synchronized so the machine 
works properly. The actions that affect the process velocity in each part of the process 
are: the cutting of the strips, for the conversion process, and the sealing of the packaging 
material to form the pouch, for the primary packaging process. 
According to the information collected form the suppliers, sealing the pouch is the 
process that has more impact on the output of the machines because it takes more time 
than the cutting of the strip that is  very quick (kiss cut). Additionally, the sealing stations 
have limited space for sealing so, if the pouch size increases, the number of pouch 
produced in every sealing cycle decreases. Very important is also the type of packaging 
material: different materials take different times to seal, higher sealing times reduce the 
machine output. In addition to all this, for changing the pouch format new spare parts 
may be needed and this means additional costs. In the Figure 26 it’s possible to see a 
schematic representation of a layout of an OTF inside of a pouch. 
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Figure 26 - Layout of a pouch with an OTF strip inside. Both dimensions represent the standard for this 
particular product (courtesy of supplier P.B). 
Thereby, it is important to have in mind that: 
 The selected packaging material must be resistant enough to protect the OTF, 
mainly when the pouch is handled and easy to seal (small temperature and 
quickly). 
 The size of the pouch must take into account the specifications of the sealing 
station to optimize the project by trying to fit in every sealing cycle the maximum 
number of pouches possible. 
 If possible, the size of the pouches should be maintained in order to maintain the 
investment in spare parts at a minimum. With the right planning this can be 
achievable because the size variation of the strips are not very significant. 
 The cost of the material is also a very important question. In some cases, the 
packaging material contributes with the higher percentage of the costs. So, it is 
very important to negotiate higher quantities in order to decrease the material 
costs and to improve the cost-effectiveness of the manufacturing process. 
Specifications of the Quoted Equipment 
The four suppliers selected for web converting and packaging equipment delivered 
quotations on both pilot (Table 16) and commercial scale equipment (Table 17). 
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Type Primary Packaging Equipment (P) 
Supplier A B C D 
Equipment P1 P1 P1 P1 
Code P.A-P1 P.B-P1 P.C-P1 P.D-P1 
Length (mm) 6770 4520 4000 3060 
Width (mm) 1500 1700 1600 1376 
Height (mm) 1700 1850 2000 2006 
Area (m2) 10,2 7,7 6,4 4,2 
Approx. Weight (kg) 7000 3000 4000 3000 
Accepted Web 
Width (mm) 
250 200 150 150 
N.º of Lanes 1 1 1 1 
Principle of 
Operation 
Continuous Continuous Intermittent Intermittent 
Slitting Station 
(option) 
No ? Yes Yes 
Adaptable for TDDS  Yes No Yes Yes 
 ndi: not delivered information 
Table 16 - Specifications of the pilot web converting and packaging equipments. 
The first two models (P.A-P1 and P.B-P1) work continuously while the last ones work 
intermittently. By the definitions we’ve seen before, this should mean that the ones that 
have an intermittent operation should have a lower capacity of production as we will 
see later on.  
All the models have just one lane of operation and a small web width. Although, this is 
still a considerable width if we take into account that OTFs are significantly smaller, 
normally not bigger with an area of 5 to 20cm2 [35]. 
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Type Primary Packaging Equipment (P) 
Supplier A B C D 
Equipment I1 I1 I1 I1 
Code P.A-I1 P.B-I1 P.C-I1 P.D-I1 
Length (mm) 10000 10000 12000 7150 
Width (mm) 1870 2500 1600 3930 
Height (mm) 2400 2000 2000 2320 
Area (m2) 18,7 25,0 19,2 28,1 
Approx. Weight (kg) ndi 6000 10000 ndi 
Accepted Web Width 
(mm) 
330 300 150 150 
N.º of Lanes 
(Maximum) 
4 3 4 3 
Principle of 
Operation 
Continuous Continuous Continuous Continuous 
Slitting Station 
(option) 
No Yes No Yes 
Adaptable for TDDS  Yes No No Yes 
 ndi: not delivered information 
Table 17 - Specifications of the commercial scale web converting and packaging equipment. 
Regarding the commercial scale models we see that the higher differences are in the 
number of lanes and in the dimensions. All 4 models work continuously. As we will see, 
the output of these machines are significantly higher, mainly because it’s possible to 
operate more than one lane at the same time. In this cases, a slitting unit in the primary 
packaging machine may not be needed because the web is already divided by the 
number of working lanes. 
It is also important to make a reference to the printing an inspection features, which are 
not specified because it exists numerous options for each one of the pilot and industrial 
machines machine and the chosen features depend on what kind of information must 
be printed. 
5.3.4 Final Remarks 
We now know how these different types of equipment work and the critical parameters 
that influence their performance. The collection of this information is very important 
because it is not readily available in any source (books, papers, internet, etc.) and 
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because it will contribute for the understanding of this non-conventional manufacturing 
process. Furthermore, it will give a very important contribution for the design of a new 
manufacturing facility dedicated to the manufacture of this novel dosage form, the first 
of its kind in Portugal.   
In a more detailed way it was possible to understand the manufacturing process and 
identify the principal requisites.  
In order to deepen even more the knowledge regarding these machines and the critical 
quality and process attributes, it is necessary to continue the contact with the suppliers, 
through more face-to-face meetings, visits to the machines manufacturing sites and 
ultimately experiment these machines. 
All the suppliers, mainly of mixing and coating equipment, offer trial services where a 
team can go to a test facility not only to try the equipment but also to adapt the 
parameters of the equipment to the desired formulation. In the case of the mixing 
equipment it’s even possible to experiment an equipment in our own facilities.  
 
5.4 Capacities Estimation 
One of the main goals of this project was to determine the necessary production 
capacity of the new manufacturing facility to meet OTFs’ forecasts.  
In order to do it, we must first estimate the annual capacity of the coating and the web 
converting and packaging equipment and then to confront it with Bluepharma’s 
forecasts until 2025.  
The calculations were made for both pilot and industrial scale. 
The methods used for these calculations were are explained in the Methodology 
chapter. 
5.4.1 Coating Equipment Capacities 
As seen before, the velocity of the coating machines depend on the dryer length. The 
higher it is, the higher the velocity will be. As we know the Velocity of the process it’s 
given by Eq. 2, 
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𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
𝐷𝑟𝑦𝑒𝑟 𝑙𝑒𝑛𝑔ℎ𝑡
𝐷𝑟𝑦𝑖𝑛𝑔 𝑡𝑖𝑚𝑒
 
So considering that the Drying Time of the Bluepharma’s formulation in a coating 
machine is 10 minutes, the annual capacity of the coating equipment is given by using 
Eq. 9 
𝐶(𝑚2) = 𝑇𝑖𝑚𝑒 (𝑚𝑖𝑛) ∗ 𝑂𝐸𝐸 ∗ 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦(𝑚/𝑚𝑖𝑛) ∗ 𝑊𝑒𝑏 𝑊𝑖𝑑𝑡ℎ(𝑚) 
Additionally, and as we’ve seen, it was considered 250 days of work per year, divided by 
weeks of 5 days. We also considered 2 and 3 shifts of 8 hours per day to have two 
scenarios. 
Table 18 gathers all the necessary data for this estimation and has the results for the 
annual capacities (in square meters of film) for each equipment model when working in 
2 shifts and in 3 shifts. 
 
Table 18 - Annual capacity of each pilot coating equipment considering 2 shifts and 3 shifts. 
Looking to Table 18, Models C.A-P1 and C.D-P1 present the lowest capacities, while 
models C.B-P1 and C.C-P1 present similar capacities. The machine C.A-P2 presents by 
Type
Supplier B C D
Equipment P1 P2 P1 P1 P1
Code C.A-P1 C.A-P2 C.B-P1 C.C-P1 C.D-P1
Drying Time BLPH 
formulation (min)
Useable Coating 
Width (mm)
120 200 250 200 100
Dryer Length(mm) 1600 3400 1660 1876 1500
Velocity (m/min) 0,16 0,34 0,17 0,19 0,15
OEE
Annual Capacity 
(m2)
2.269          8.036          4.905          4.434          1.773          
Average
OEE
Annual Capacity 
(m2)
4.424          15.667       9.562          8.645          3.456          
Average 8.351
Coating Equipment (C )
64,00%
A
10
2 Shift Operation
3 Shift Operation
49,24%
4.283
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far the higher capacity when compared with all the other options – 8.036m2 and 
15.667m2. Another important thing to notice is the enormous difference between a 
production with 2 shifts and with 3 shifts. This due to the higher time of production, and 
also because of the OEE that is also significantly different by the reasons explained in 
the Methodology: the equipment has to stop more times what increases its downtimes. 
To facilitate the comparison between each machine, results are also displayed in Graphic 4 
 
 
Graphic 4 - Calculated annual capacity for each pilot coating equipment, considering 2 or 3 shifts and 
respective averages. 
Concluding, we can say that C.A-P2 model is by far the option with the highest capacity, 
and that the average capacity for a 2 shift operation is 4.283m2 and 8.351 m2 for 3 shifts. 
We can say, that in average these models produce 94% more when running in 3 shifts 
than when just work 2 shifts per day. Almost the double. 
The Next table, Table 19, displays the estimations for the annual capacity of each 
industrial scale model working in 2 or 3 shifts.  
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Table 19 - Annual capacity of each pilot coating equipment considering 2 shifts and 3 shifts. 
From the four models analyzed, we can notice that the capacities calculated are very 
heterogeneous. However, model C.B-I1 is clearly the one that ensures the highest 
annual capacity, followed by the C.A-I2.  Like in the pilot equipment, the difference 
between 2 and 3 shifts of operation is enormous.  
Analyzing this table we can notice that the coating width, the dryer length and the 
velocity are significantly higher than the values of Table 18, for pilot equipment.  
In fact, looking to the Graphic 5, we realize that the industrial equipment can produce, 
in average, ca. 8 times more area of film than the pilot equipment (if we compare the 3 
shift operation capacities). 
Type
Supplier B C
Equipment I1 I2 I1 I1
Code C.A-I1 C.A-I2 C.B-I1 C.C-I1
Drying Time BLPH 
formulation (min)
Useable Coating 
Width (mm)
440 440 500 460
Dryer Length 
(mm)
4700 8500 9000 3810
Velocity (m/min) 0,47 0,85 0,90 0,38
OEE
Annual Capacity 
(m2)
24.440       44.200       53.182       20.713       
Average
OEE
Annual Capacity 
(m2)
47.647       86.170       103.681     40.380       
Average
Coating Equipment (C )
69.469
2 Shift Operation
3 Shift Operation
10
64,00%
49,24%
35.634
A
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Graphic 5 - The annual capacities of each industrial coating equipment, working in 2 or 3 shifts and 
respective averages. Also it's represented the average of the 3 shifts operation of pilot equipment. 
In the coating process, the size of the film for each product may vary and so it is best to 
estimate the annual capacity in area than in number of films. Nevertheless it may be 
important to have a notion of how many strips those capacities represent. Graphic 6 and 
Graphic 7 show the conversion of the area to the corresponding number of OTF of a 
standard size of 20x30 millimeters and a wasted area of 20%, as explained in chapter 4. 
  
Graphic 6 - Number of OTFs that correspond to the produced area of each pilot coating equipment. A 
standard size of 20x30mm per OTF was considered as well as a film waste of 20%. 
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Graphic 7 - Number of OTFs that correspond to the produced area of each industrial coating 
equipment. Was considered a 20x30mm OTF and a film waste of 20%. 
There is an enormous difference separating the two scales. The best pilot option (C.A-
P2) can produce enough area for more than 20 million OTFs, while the best industrial 
solution (C.B-I1) can produce an annual area of film for more than 160 million OTFs. 
Another important thing to take from this charts, is that the pilot equipment can 
produce, during the year, several pilot batches. The pilot batches are an important 
requirement, because they are necessary to validate the manufacturing process. 
Normally, a pilot batch need to have at least 100.000 product units [36]. In addition, the 
high capacities of the pilot equipment makes it a good option for low productions and 
niche products. 
5.4.2 Packaging Equipment Capacities 
As referred in the methodology chapter, the capacity of this type of equipment (number 
of OTFs delivered by each machine inside a pouch) is given by the Eq. 10: 
𝐶(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑂𝑇𝐹𝑠) = 𝑇(min) ∗ 𝑂𝐸𝐸 ∗ 𝑁𝑜𝑡𝑓(
𝑂𝑇𝐹
𝑚𝑖𝑛
) ∗ 𝑁𝑙 
Ns is the number of strips delivered in a certain range of time and the NL it’s the 
maximum number of lanes which the machine can run.  
For these calculations we’ve assumed again the standard strip size of 20x30 millimeters. 
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We already seen the meaning and advantages of the Overall Equipment Effectiveness 
indicator. Although, we choose to use in this estimation the OEE of Bluepharma. 
𝑂𝐸𝐸 𝐵𝑙𝑢𝑒𝑝ℎ𝑎𝑟𝑚𝑎 = 35% 
Bluepharma only measures the OEE for packaging. The value is significantly lower than 
the one we estimated for the production. However, this is an acceptable value for the 
packaging phase in the pharmaceutical industry. In fact, reports say that generally 
packaging OEE in pharma goes from 15% to 45% [37]. Also the suppliers confirmed this 
information and explained us that this low OEE it’s due to the fact that there is a lot of 
unexpected stops because of the complexity of these machines and also because the 
packaging is always dependent on the production. 
Table 20 gathers all the necessary data for the capacity estimation of the pilot primary 
packaging equipment. In the same table are presented the results for the annual 
capacities (in number of OTFs) for each equipment when working in 2 shifts and in 3 
shifts.  
Type Primary Packaging Equipment (P) 
Supplier A B C D 
Equipment P1 P1 P1 P1 
Code P.A-P1 P.B-P1 P.C-P1 P.D-P1 
Pouches per Minute 100 100 75 40 
N.º of Lanes 1 1 1 1 
Pouches per Hour 6.000 6.000 4.500 2.400 
2 Shift Operation 
OEE 35% 
Annual Capacity 
(OTFs) 
        8.400.000            8.400.000            6.300.000            3.360.000    
Average 6.615.000  
3 Shift Operation 
OEE 35% 
Annual Capacity 
(OTFs) 
      12.600.000          12.600.000            9.450.000            5.040.000    
Average 9.922.500  
Table 20 - Annual capacities of the pilot primary packaging machine, in number of OTFs. 
All the models analyzed have only one lane, and the maximum output claimed by the 
suppliers don’t surpass the 100 pouches per minute. Models P.A-P1 and P.B-P1 present 
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the same capacity. In the next chart it’s easy to compare all the different equipment 
capacities. 
 
Graphic 8 - The annual capacities of the pilot equipment for primary packaging and the respective 
averages, in number of OTFs and considering a standard strip of 20x30 mm. 
None of the machines, when working in two shifts can reach the 10 million of OTFs/year, 
while the two first models can surpass the 12 million OTFs /per year if a 3 shift operation 
is considered. We can conclude that those two machines would be able to convert and 
pack the average area of film produced by the pilot coating machines in one year, as 
showed in the Graphic 6. However, none of the options can assure the packaging of the 
films manufactured during one year with coating equipment C.A-P2 in 3 shifts. 
The next table (Table 21) displays all the needed information to calculate the capacities 
of each industrial equipment. 
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Type Primary Packaging Equipment (P) 
Supplier A B C D 
Equipment I1 I1 I1 I1 
Code P.A-I1 P.B-I1 P.C-I1 P.D-I1 
Pouches per Minute 250 300 300 200 
N.º of Lanes 4 3 4 3 
Pouches per Hour 60.000 54.000 72.000 36.000 
2 Shift Operation 
OEE 35% 
Annual Capacity 
(OTFs) 
      84.000.000          75.600.000        100.800.000          50.400.000    
Average 77.700.000  
3 Shift Operation 
OEE 35% 
Annual Capacity 
(OTFs) 
    126.000.000        113.400.000        151.200.000          75.600.000    
Average 116.550.000  
Table 21 - Annual capacities of the industrial primary packaging machine, in number of OTFs. 
The industrial scale packaging equipment has, in average, an output ca. 12 times higher 
than the pilot scale equipment, with 3 of the models analyzed exceeding the 100 million 
of OTFs. 
 
Graphic 9 - The annual capacities of the industrial equipment for primary packaging in number of OTFs 
and the respective averages. It was considered a standard size of 20x30 millimeters. 
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The model P.C-I1 is the one with the highest capacity, ca. 150 million OTFs per year, at 
full capacity (3 shifts). The model P.D-I1 from supplier “D” is the one with the lowest 
capacity. The same happened in the pilot scale. 
Only equipment P.C-I1 will be able to convert the area produced during one year and 
working in 3 shifts by the most powerful coating equipment, the C.B-1. 
 
5.4.3 Final Remarks 
From the analysis of these results it is possible to conclude that the limiting step of OTFs 
production is the web conversion and the primary packaging. This means that what will 
define the number of products produced in one year is the capacity of the web 
converting and packaging equipment. It’s also important to refer that these estimations 
have some limitations:  
 The drying time considered for the coating process (T=10min) is significantly 
higher than the normal values for OTFs. This assumption was made due to 
composition of Bluepharma’s technology and considering a worst case scenario. 
 If it is possible to reduce the drying time for example to T=5min, the velocity of 
the process in each machine would duplicate and the annual capacity too.  
 On the contrary, it is not possible to significantly increase the capacity of the 
primary packaging equipment. Depending on the pouch size and material better 
outputs can be achieved, but those variations are not in the same order of 
magnitude as in the case of the coating machines. 
In a normal scenario of an industrial production of OTFs, with one coating machine and 
one primary packaging machine, it is this second equipment performance that will 
determinate the annual capacity of the production process. 
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5.5 Bluepharma Forecasts 
 
Graphic 10- Bluepharma's Forecasts from 2018 to 2025. 
Currently, the company has four products in pipeline, which will be referred by their 
code names BlueOS1, BlueOS2, BlueOS3 and BlueOS4, due to confidential reasons. 
Looking to the Graphic 10 we can have an idea concerning the expected sales evolution 
of OTFs until 2025. This prediction points to the launch of BlueOS1 in 2018, BlueOS2 in 
2019, BlueOS3 in 2021 and BlueOS4 in 2022. It’s also easily spotted that BlueOS03 is by 
the best-selling product, followed by BlueOS01. Another important point is the total 
number of OTFs predicted for 2025 – near 100 millions of strips. Further we will see the 
concrete numbers for each year and each product (Table 23) 
At this point it’s important to remember that the method of calculation of the capacities, 
as we’ve seen before, is different from coating to web converting and primary 
packaging. In the first case the unit used is square meters of film (m2) and in the second 
case the unit is the number of OTFs. 
Once the forecasts provided by Bluepharma are represented in number of OTF, they can 
just be directly compared with the primary packaging capacities. In order to use this 
forecasts for a comparison with the coating capacities estimated, we must convert it 
into area of film. 
To do this we must follow the procedure explained in the Methodology chapter and 
apply the Eq. 12: 
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𝑇𝑜𝑡𝑎𝑙 (𝑎𝑟𝑒𝑎) = 𝛴(𝑁(𝑂𝑇𝐹𝑠) ∗ 𝑂𝑇𝐹 𝐴𝑟𝑒𝑎) + 20% 
The Table 22 - Bluepharma OTFs sizes and areas. 
Table 22 shows the different sizes and areas of the different BlueOS. As it possible to 
see, not all of them have the final size approved, so we considered for those cases 
(BlueOS3 and BlueOS4) a standard strip size of 20x30mm. 
  BlueOS1 BlueOS2 BlueOS3 BlueOS4 
Strip Size 
(mm) 
12,8x22 
15x20 20x30* 20x30* 19,2x22 
25,6x22 
Strip Area 
(m2) 
2,82E-04 
3,00E-04 6,00E-04 6,00E-04 4,22E-04 
5,63E-04 
 *standard strip 
Table 22 - Bluepharma OTFs sizes and areas. 
With the information of Table 22 we can now apply the Eq. 12 and convert Bluepharma’s 
forecasts to area of film. The fact that the BlueOS1 presents 3 different sizes, it’s because 
this product will be marketed in different doses and each size means a different dose of 
the product.  
Thereby, in the next two tables (Table 23 and Table 24) it’s shown the company forecasts 
in number of OTFs and area of film, respectively. 
Year 2018 2019 2020 2021 2022 2023 2024 2025 
BlueOS1 17.580.000 18.810.000 24.960.000 24.960.000 24.960.000 24.960.000 24.960.000 24.960.000 
BlueOS2   3.782.352 4.181.968 4.571.476 4.749.556 4.917.556 5.085.556 5.253.556 
BlueOS3       27.417.840 34.272.300 41.126.760 47.981.220 54.835.680 
BlueOS4         4.048.400 6.072.600 8.069.700 10.120.900 
TOTAL 
(OTFs) 17.580.000 22.592.352 29.141.968 56.949.316 68.030.256 77.076.916 86.096.476 95.170.136 
Table 23 - Bluepharma's forecasts for each product. 
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Year 2018 2019 2020 2021 2022 2023 2024 2025 
BlueOS1 6.559 7.010 9.306 9.306 9.306 9.306 9.306 9.306 
BlueOS2   1.362 1.506 1.646 1.710 1.770 1.831 1.891 
BlueOS3       19.741 24.676 29.611 34.546 39.482 
BlueOS4         2.915 4.372 5.810 7.287 
TOTAL 
(m2) 6.559 8.372 10.812 30.693 38.607 45.060 51.494 57.966 
Table 24 - Bluepharma's sales forecast converted to area of film. 
The areas calculated (Table 24) will be used to analyze the capacities of the different 
coating models while the values of Table 23 will be used to do the same exercise but 
with the primary packaging equipment. 
5.6 Equipment Capacity V.S. Bluepharma Forecasts 
The purpose of this confrontation it’s to determine if the coating and primary packaging 
equipment models analyzed in this project can guarantee, or not, the predicted 
production of Bluepharma. For that, a series of timeline tables that display if a 
determined machine can ensure the company’s forecast in each of the years, will be 
presented. 
5.6.1 Coating Equipment 
Table 25 shows the forecast for the area of film that is necessary to be manufactured in 
each year. Then, the models of the pilot coating equipment are considered at the left 
side of the table, for 2 shift and 3 shift operations. 
Year 2018 2019 2020 2021 2022 2023 2024 2025 
TOTAL (m2) 6.559 8.372 10.812 30.693 38.607 45.060 51.494 57.966 
P
ilo
t 
sc
al
e 
2 Shift Operation 
C.A-P1 n n n n n n n n 
C.A-P2 y n n n n n n n 
C.B-P1 n n n n n n n n 
C.C-P1 n n n n n n n n 
C.D-P1 n n n n n n n n 
3 Shift Operation 
C.A-P1 n n n n n n n n 
C.A-P2 y y y n n n n n 
C.B-P1 y y n n n n n n 
C.C-P1 y y n n n n n n 
C.D-P1 n n n n n n n n 
Table 25 - Confrontation between the pilot coating equipment capacities and the company's forecasts. 
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The green cells with a “y” means that the equipment in that line can ensure the 
necessary production for that year. On the contrary, the red cells with an “n” means that 
the equipment alone does not have the necessary capacity for the projected production 
for that year. For example, the model C.A-P2 when working 2 shifts per day, can ensure 
the full production of the year 2018, but not in any of the other years. 
Looking again to Table 25, we conclude that with a 2 shift operation, only model C.A-P2 
is able to produce the required quantity, but only in the first year (2018). Considering a 
3 shift operation, this machine is able to assure the production of OTF until 2020, and 
models C.B-P1 and C.C-P1 can assure it until 2019.  
In conclusion we can say that pilot coating equipment is not a suitable option in the long 
term, but it can be a possibility for the first years of production. Plus, it can be used to 
produce pilot batches and niche products. 
Year 2018 2019 2020 2021 2022 2023 2024 2025 
TOTAL 6.559 8.372 10.812 30.693 38.607 45.060 51.494 57.966 
C
o
m
m
er
ci
al
 s
ca
le
 E
q
u
ip
m
en
t 
2 Shift Operation 
C.A-I1 y y y n n n n n 
C.A-I2 y y y y y n n n 
C.B-I1 y y y y y y y n 
C.C-I1 y y y n n n n n 
3 Shift Operation 
C.A-I1 y y y y y y n n 
C.A-I2 y y y y y y y y 
C.B-I1 y y y y y y y y 
C.C-I1 y y y y y n n n 
Table 26 - Confrontation between the industrial coating equipment capacities and the company's 
forecast. 
When considering the industrial coating equipment, the results are totally different, as 
showed in the Table 26. All the models have the necessary capacity for the full industrial 
production of the projected amounts of OTFs until 2020, for a 2 shift operation, and until 
2022, if 3 shits per day are considered. Nevertheless, it’s important to refer that in the 
first case, none of the options can guarantee the production in all of the years, while in 
the 3 shift operation, only two models (C.A-I2 and C.B-I1) can satisfy the full production 
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until 2025. This evaluation is important not only to have an estimation of the overall 
budget for the project but also for dividing the budget per year. 
5.6.2 Primary Packaging Equipment 
Table 27 displays if the different pilot scale models can or cannot support the predicted 
full production for each year. As we know at this point, this analysis is made in number 
of OTFs and not in area of film. 
Year 2018 2019 2020 2021 2022 2023 2024 2025 
TOTAL 17.580.000 22.592.352 29.141.968 56.949.316 68.030.256 77.076.916 86.096.476 95.170.136 
P
ilo
t 
Eq
u
ip
m
en
t 
2 Shift Operation 
P.A-P1 n n n n n n n n 
P.B-P1 n n n n n n n n 
P.C-P1 n n n n n n n n 
P.D-P1 n n n n n n n n 
3 Shift Operation 
P.A-P1 n n n n n n n n 
P.B-P1 n n n n n n n n 
P.C-P1 n n n n n n n n 
P.D-P1 n n n n n n n n 
Table 27 - Confrontation between the pilot primary packaging equipment capacities and the 
company's forecast. 
None of the pilot scale equipment is able to ensure complete production in any year. 
This tells already that the investment in an equipment like this is not enough even in the 
short term for the packaging of the commercial scale production. 
Year 2018 2019 2020 2021 2022 2023 2024 2025 
TOTAL 17.580.000 22.592.352 29.141.968 56.949.316 68.030.256 77.076.916 86.096.476 95.170.136 
In
d
u
st
ri
al
 s
ca
le
 E
q
u
ip
m
en
t 
2 Shift Operation 
P.A-I1 y y y y y y n n 
P.B-I1 y y y y y n n n 
P.C-I1 y y y y y y y y 
P.D-I1 y y y n n n n n 
3 Shift Operation 
P.A-I1 y y y y y y y y 
P.B-I1 y y y y y y y y 
P.C-I1 y y y y y y y y 
P.D-I1 y y y y y n n n 
Table 28 - Confrontation between the industrial primary packaging equipment capacities and the 
company's forecast. 
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Table 28 shows the results for the industrial scale primary packaging machines. In a 2 
shift operation, just the model P.C-I can assure full production in all the years of the 
forecast. But if we operate with 3 shifts per day, three of the four machines have the 
necessary capacity to ensure the production forecasts. Only the machine P.D-I1 can’t 
produce all the OTFs in all the considered years. 
5.6.3 Final Remarks 
It is clear the need of an investment in an industrial scale equipment since the early 
years. Some of the models analyzed still have some capacity remaining that can also 
support a significant increase in the production when compared to the forecasts. 
Considering all these we can conclude that the following models fulfill all the 
requirements for Bluepharma’s new manufacturing facility: 
 Coating Equipment: C.A-I2 and C.B-I1; 
 Primary Packaging Equipment: C.A-I1, C.B-I1, C.C-I1. 
Nevertheless, the acquisition of pilot scale equipment for the coating, web converting 
and packaging will be necessary to perform the scale up of the manufacturing process 
of all new products.  
 
5.7 Road-Map 
With the equipment’s capacities estimated and crossed with the sales forecasts of the 
company, it’s now possible to trace a road-map. By road-map we mean a timeline map 
with the equipment acquisition milestones identified. In this map are presented the 
needed scales and not the individual equipment. 
The Figure 27 illustrates the resulting road-map of the project. 
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Figure 27 - Project Road-Map until 2025. It's possible to see the products launch and the equipment 
needs. 
Looking to the Figure 27, the most important conclusion we can take is that by 2021, 
Bluepharma must be fully equipped (industrial scale equipment), in order to produce 
the expected forecasts of OTFs. 
The mixing equipment obviously follow the scale of the coating equipment. It was 
considered by the company that 2 pilot mixers and 2 industrial mixers (one of 500L and 
other of 1000L) should be acquired. 
One pilot coating machine can guarantee the first three years of industrial production, 
which minimizes the initial investment. After that, by 2021, industrial scale equipment 
is necessary to ensure the production.  
In what concerns the primary packaging equipment, an industrial machine is needed to 
ensure the company forecasts since the beginning. Although, it is necessary the 
acquisition of a pilot scale machine for scale-up purposes.  
To conclude, this road-map give us an outlook of the crucial milestones in terms of 
equipment needs. Future changes in the forecasts or in the estimation of the capacities, 
can affect, obviously, the planned road-map. For those reasons, this exercise must be a 
continuous process.  
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5.8 Investment Analysis 
Table 26 shows the range of investment necessary for each type of equipment and 
according to their scale. Due to confidential reasons it’s not possible to present the 
prices for each one of the models analyzed. 
 
Figure 28 - Investment range table. Each range displays the lowest and the highest budgetary 
quotation received for that type of equipment and its respective scale. 
Each range displays the lowest and the highest budgetary quotation for that equipment 
type. All the models analyzed in this project were considered to this investment analysis. 
Crossing this information with the road-map, we can get the investment road-map. 
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Figure 29 - Road-Map of investment. Shows the necessary investment needed in order to fulfil the 
sales forecasts. In the bottom it is also possible to see the global investment range (in equipment 
only). 
Figure 29 shows us when and how much the company has to invest in equipment, in 
order to fulfill the expected production of OTFs. 
As described above, there are two main investment milestones, the first is in 2018 and 
the second is in 2021. The necessary investment in a pilot coating machine, in an 
industrial primary packaging machine and in 2 pilot mixers of 50L represents an 
investment ranging from approx. 1 Million Euros to approx. 2.7 Million Euros. Three 
years from that, an industrial machine for coating is needed. The option for a mixer of 
500L and another of 1000L was decided by the company. This investment may reach 
approx. 2.2 Million Euros in the more expensive solution and around 1.2 Million if all the 
less expensive equipment is acquired considering today’s quotations. 
Concluding, the global investment range in equipment can go from 2.287.687,00 € to 
4.956.750,00 €.  
The investment described before represents only the investment in mixing, coating and 
primary packaging equipment taking into account the company forecasts. These are not 
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the only costs for the set-up of the new manufacturing facility. Building a facility involves 
several other investments (e.g. building, air systems, etc) and other types of equipment 
not included here such as the secondary packaging machines and the slitting machines. 
Additionally, and as said before, it is also planned the acquisition of a pilot primary 
packaging machine for scale-up purposes. 
According to Bluepharma’s know-how, the additional estimated costs must be 
considered: 
 Facility building costs: approx. 1.500.000,00€; 
 Other infrastructures: approx. 500.000,00 €; 
 Pilot primary packaging machine: from 494.800,00 € to 886.415,00 €; 
 Other equipment (i.e. secondary packaging machine): approx. 500.000,00 € 
Adding these costs to the investment already considered, we will get the total 
investment range necessary to implement a facility for the production of oral thin films 
(Table 29). 
 
Table 29 - Total investment range and average value for setting up the new manufacturing facility.  
It’s important to refer that the facility building costs presented took into account the 
space needs that resulted of our outline design of the manufacturing facility, which can 
be seen in the next chapter.   
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5.9 Outline Design of the Manufacturing Facility  
 The design of the new manufacturing facility must be an integrated design that satisfies 
process and equipment layout requirements (already discussed in this thesis), 
operational access requirements,  maintenance access requirements, personnel flows, 
material flows (product, component and raw materials movements). For the definition 
of operational access and maintenance requirements as well as personnel and materials 
flows it was very important the support of experienced professionals from Bluepharma 
and some examples of layouts for the manufacturing of the same dosage forms.  
Figure 30 shows a small lab for development of OTFs. This information was provided by 
one of the suppliers. It’s possible to see, in the left, a laboratory machine for coating and 
other for web converting and primary packaging (punch and pouching). On the right side 
is the mixing station.  
 
 
Figure 30 - Design of a laboratory for the development of OTFs with approx. 25m2 of area. a) mixing 
equipment. b) lab coating machine. c) lab primary packaging machine (courtesy of supplier C.A). 
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Figure 31 - Draw of a medium industrial installation for the production of OTFs with approx. 432m2 of 
area (courtesy of supplier C.A). 
Figure 31 shows a medium size (432 m2 of total area) manufacturing facility for the 
commercial scale of OTFs. The rooms A and B is where the release liner rolls and the 
mixing ingredients are delivered. It must be separated rooms because each type of 
product will follow a different flow - the release liner follows to the coating room E and 
the mixing ingredients go to the mixing room C. The room D is the Quality Control (QC) 
room. For our project it will not be considered because the QC will be in the actual 
facility. On the center it’s possible to see the coating room (E) with the coating machine. 
It has a technical room, one of the critical aspects as we will see. The room F is a depot 
to store the coated film rolls before they go to conversion and packaging. The web 
converting and primary packaging machine is located on room G and it is also possible 
to find a cartoning machine for the secondary packaging, where the pouches are putted 
inside of boxes. The final product (OTF box) it’s then put in pallets (room H) and stored 
in the outgoing depot (I) to be shipped. This plant was also provided by the same supplier 
that provided the laboratory plant. 
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For easier understanding of the process flow we should look to Figure 32 where it is 
possible to have an overview of how the manufacturing process that occurs in that 
layout.  
 
 
Figure 32 - Quick view of the manufacturing process flow. Each number has the correspondent legend 
on the right. 
This image is important, because it shows that there was a logic in the projection of the 
facility. It follows a constant and direct path in order to optimize the space available. 
Gathering all these information and data it was possible to make an outline concept 
design of a one floor manufacturing facility for the development, scale up and 
commercial scale manufacturing of Bluepharma’s OTFs with the dimensions appropriate 
according to the company forecasts.  
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Figure 33 - Outline concept design of a facility for the development and production of OTFs at lab, pilot and 
industrial scale. 
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Figure 34 - Outline concept design of a facility for the development and production. The letters and 
number in this figure help to understand the following text 
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Figure 33 and Figure 34 show the concept plant of the manufacturing facility designed 
for this project. The second image has letters that will help to understand the next 
paragraphs. 
The first concern was, of course, the space. As we have seen, machines have very 
different areas. Thereby, we decides to represent the ones with higher areas and 
consider the possibility to expand the capacity in the future. The coating machines (pilot 
and industrial) are represented in orange and the primary packaging equipment in dark 
blue. Also, a secondary packaging machine it’s represented in light blue and the mixers 
and buffer tanks in green. 
Also in this image there are several rolls represented: the ones in brown represent the 
release liner. The orange ones the coated film rolls, i.e. the release liner already with the 
film on it. Finally the dark blue rolls represent the packaging material. 
We separated the laboratory area from the rest. So it’s considered that pilot and 
industrial scale are both in the production zone of the facility. This must be like this 
because even though pilot scale represents a lower scale, it must also comply with the 
GMP. 
The staff entry (and exit) is made through Ent1/Exit1. People that work in the laboratory 
enters to the lab zone (L) through the locker room L1 and the production personnel 
through L2 locker room. These happens because lab and production have different 
requirements. Plus, they are two independent activities and it’s recommended to have 
them separated. 
As already said before, a Quality Control (QC) room is not necessary in this plant, 
because it will be located in other adjacent facility.  
The second entry of the facility (Ent2) is the door for the entry of the production raw 
materials and the release liner (for coating and mixing). The release liner is stored in the 
depot room D1 and the materials for the mixing process are stored in a second depot, 
D2. They must be separated first because they will follow different paths (the release 
liner goes directly to the coating room (C) and the mixture ingredients to the mixing 
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room (M)) and second because the mixing ingredients are often very sensitive and 
should be stored in more controlled conditions. 
The plant presents one more entry (Ent3) that is dedicated exclusively for the packaging 
material. This happens due to the proximity to the packaging zone (PP and SP) but mainly 
because this material should be separated from the production raw materials for safety 
reasons. Much of this material is carton and paper for the secondary packaging and can 
liberate dust and other particles that could contaminate other products. These materials 
are stored in the depot D4. 
The D3 depot is where the coated film rolls are kept after the coating process. They must 
be stored in a controlled room in order to preserve the film. According with the 
contacted suppliers if the film doesn’t contain organic components it can be stored for 
a long period, normally more than six weeks. If there are organic components on the 
film formulation, the conversion to strips and primary packaging should happen until 
forty eight hours after end of coating process. 
Looking again to the top of the plant, W1 and W2 are two weighing rooms to weigh the 
different components of the formulation with weighing machines with different sizes 
and precisions in order to serve the different scales. They are next to the mixing room 
for convenience. 
There are two cleaning rooms (Cl1 and Cl2). The first is located in the top of the plant 
and serves the mixing area. The second is located near the coating and the packaging 
areas and it’s supposed to be used to clean the mixture tanks after they are used in the 
coating process and to clean other equipment or tools of the coating and packaging 
processes. 
In what concerns the mixing area (M), it must have the necessary space to accommodate 
pilot scale and industrial scale mixing equipment. As we have seen industrial mixers can 
go to thousands of liters. If we have only one pilot mixer it’s recommended to have two 
portable buffer tanks. In this way, after the mixture in the reactor is finished it can be 
discharged to a tank that will be transported and connected to the coating machine. The 
reactor can then be cleaned and used again. When finished it can be discharged to the 
other buffer tank as the first one goes to clean. For industrial mixers transportable buffer 
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tanks can also be used, however it’s recommended that the mixture is discharged to big 
buffer tanks that are fixed. These last ones in their turn, are directly connected to one 
(or more) coating machine through a complex system of pipes and pumps that guide the 
mixture directly from the deposit to the coating head pump. In the Figure the industrial 
mixers are represented by the letter “m” and the buffer tanks, connected to the coating 
room, by the letter “b”. Also, smaller mixers and buffer tanks (for pilot production) are 
represented in this floor plan. 
The coating rooms (C) are the areas where the coating equipment are placed. Due to 
the contact with the suppliers we were also able to collect some important information 
on the requisites of those zones: 
 Technical room (T): the coating machines often need small adjustments and 
have a very complex air ducts. Thus, it’s recommended to have a physically 
separated technical area from the coating room with an independent 
entrance. The back of the coating machine should fit through the physical 
barrier so it can be accessed through the technical room. 
 The place where the coating machine operates must be a closed cleanroom. 
A cleanroom is a controlled environment normally used in the most diverse 
industries, where the level of micro particles (as dust, pollutants, etc.) are 
maintained at very low levels. To guarantee this, and as the suppliers 
explained, HEPA (high-efficiency particulate arrestance) air filters systems 
are placed in the room. In the case of OTF production this rooms must be 
cleanrooms class 10.000 (by USA regulation) or Class B (by EU GMP 
guidelines). This means, that an area of one cubic feet can’t have more than 
10.000 particles equal or superior than 0,5um or, by the European guidelines, 
on cubic meter can’t have more than 350.000 particles of 0,5um when the 
machine is operating. Due to all this, these rooms should have proper air 
handler units (AHU) that together with HEPA systems can regulate the quality 
of air in the room and also its temperature and humidity.  
 Despite of the quality of the air in the room, the coating machines’ dryers are 
closed systems with their own AHUs that suck the air from the room, heat it 
and then the hot air is expelled (together with the solvents) to outside of the 
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facility. Also inside the coating machine, the air quality should be class 
10.000. This means that the air sucked from the room, which in theory is 
already a “cleaned” air, passes again in the filters of the coating machine air 
system. This happens because it’s crucial that the air is always clean and in 
circulation, to reach a high quality drying process with hot air. Normally, the 
volume of air changed every hour is 8 times the volume of the room. 
 The room pressure should be normal but the pressure inside the dryer of the 
coating machine must be negative, this means lower than room pressure. 
This happens mainly because of safety reasons, preventing contamination.  If 
a door of the dryer opens or there is a fugue, the air inside the dryer (that 
may contains dangerous components for the health) will not escape to the 
outside. On the contrary, the air of the room will get inside the dryer so the 
pressure reaches an equilibrium. This is another reason why the air in the 
room has the same quality as the air inside the coating machine. 
 The recommend temperature for the room is 22ºC and the humidity 55%. 
 
Primary Packaging equipment doesn’t have a closed air system, like the coating 
machines. Nevertheless, the web converting process is still considered part of the 
production process. Thereby, for the rooms where these machines are placed (PP) all 
the suppliers recommend to have the same cleanroom conditions as in the coating 
process. This means that the room where the machines is placed should also be a clean 
room class 10.000.   
Also, there is no need for a technical area, because the adjustments on the machine are 
made through the front part by opening the machine doors. Nevertheless there are 
other manufacturing aspects that must be considered: 
The secondary packaging room (SP) has the secondary packaging equipment where the 
pouches are placed into carton boxes. All the suppliers told us that this area must be 
physically separated from the primary packaging room (PP). This is explained by the fact 
that the secondary packaging material (normally carton) may release dust and other 
particles into the air that can contaminate the OTF strips before they’re sealed into the 
pouch. To optimize the process, it’s normal that the physical barrier between the two 
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rooms have a very small opening were the conveyor that comes from the primary 
packaging machine passes through, connecting the two machines. The air pressure in 
the primary packaging room should be higher than in the secondary packaging room, so 
the air from this last one does not get into the primary packaging room though the 
referred opening. 
 
To conclude, the facility has approx. 35m by 36m, which represents a total area of 
approx. 1260m2. 
5.9.1 Final Remarks 
It is important to refer that there are still many more things to consider. The 
manufacturing of pharmaceutical products involves a lot of regulations, rules and well 
defined procedures, like the implementation of the Good Manufacturing Procedures 
(GMP). It was not an objective to look to all of these requirements and moreover, 
Bluepharma have a considerable internal know-how in the production of oral dosage 
forms with the highest standards of quality.  
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6 Conclusions 
6.1 Main Conclusions 
The following bullets resume the main conclusions of this dissertation: 
 There is a clear geographical division between the OTF manufacturers and the 
equipment suppliers; 
 The models analyzed are comparable to each other and can assure a proper 
scale-up; 
 The critical requisites were identified and will contribute to a deeper 
understanding of the manufacturing process and to the design of a new facility, 
the first in Portugal; 
 The output of the coating machines depend directly on the drying time and 
conditions, while in the primary packaging machines the output it’s mainly 
determined by the pouch characteristics. This means that the coating process it’s 
directly related with the type of the formulation; 
 The limiting step of the manufacturing process it’s the primary packaging. 
Thereby, the maximum annual capacity it’s approx. 150M OTFs;  
 The output of the industrial machines, when compared with the pilot equipment, 
is ca. 8 times higher for the coating equipment and ca. 12 higher for the primary 
packaging equipment; 
 The capacity estimation of the coating machines can be significantly increased, 
but not for the primary packaging equipment; 
 There are equipments that can meet Bluepharma’ sales forecasts.  
 Pilot equipment it’s an option for the coating process but not for the primary 
packaging process. However, by 2021 a complete industrial line it’s needed to 
fulfill the company forecasts; 
 There is no direct relation between the output and the investment of the three 
types of equipments analyzed; 
 The global investment range goes from 5,2M€ to 8,3M€ (approx.). 
 Considering the biggest equipment models, the facility must have approx. 
1200m2 of area. The critical process requisites were also identified. 
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6.2 Personal Considerations 
In what concerns the objectives of this project, I would say that the results are positive 
and surpassed my expectations: 
 The major players in this area were identified as well as the principal suppliers of 
equipment. I believe this information improves understanding that the company 
has about the this particular environment; 
 Thirty nine different equipments were studied during the duration of this 
project. For each one of those models it was received an official budgetary 
quotation with very technical information and, of course, the investment 
involved. Through the analysis of those long documents we were able to 
understand more and more of each type of equipment and, thereby, identify the 
most critical aspects and how they determine the output; 
 Consequently to the previous point, we were able to understand how to 
estimate the capacities of the equipment by applying a consistent method. Even 
though there are many factors that can contribute to the output of each 
machine, I truly believe that the results we got were extremely accurate if we 
take into account the internal information available at the time of this project. 
The company has now the clear notion of what each scale of production 
represents in terms of capacity. 
 It was determined the range of investment in equipment and was also estimated 
the global investment of the complete facility. Even though that for confidential 
reasons we can’t reveal the prices of each equipment, the results give a clear 
notion of what the company should expect for this project in terms of 
investment. I believe this an important legacy of this project that can help the 
company in future decisions; 
 The outline of the new facility was a big challenge. It was not the objective to 
have a detailed floor plan of it, but the result gives the company already 
important information, like the space needed and can serve as a good basis for 
the future. Additionally to the requirements in terms of space, it was possible to 
identify several manufacturing requisites for this technology. This part was 
another big challenge for me, which made me go into the field several times, talk 
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with very expert people in the company and make a lot of experiences until 
achieving the presented result. 
It was the main objective of this project to leave in the company a work that could serve 
has basis for the future implementation of a new facility. I place my confidence that this 
goal was accomplished. The results in this thesis were also presented to the company 
and received very positive feedbacks. 
These last nine months were undoubtedly an enormous challenge and one of the most 
learning experiences I have ever had. I had full support of the company during my 
trainee and freedom to develop my work. The guidance I had during the project was of 
extreme quality and availability, which helped me in every step. I was also completely 
integrated in the company’s routine and I was able to learn what means to work in a top 
level company. For all this reason I’m extremely satisfied with the experience and the 
resulting work. 
6.3 Future Work 
There is still a long way to go and more knowledge is still necessary. Thereby, several 
tasks are suggested for future work in this project: 
 To reduce the number of suppliers and consequently the investment range, 
through face-to-face meetings, visits to the factories and benchmarking; 
 To improve the manufacturing facility concept design through trained people in 
architecture and engineering; 
 Start a procurement process for secondary packaging material and slitting 
stations; 
 Gather information about the pouch size and material in order to determine 
more accurately the sealing time; 
 To improve the accuracy of the considered drying time in the coating process. 
It can be made, for example, in a pilot facility of a supplier. 
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7 S.W.O.T. Analysis 
To conclude, S.W.O.T. analysis was made, to evaluate the strengths, the weaknesses, 
the opportunities and threats of the OTFs project in the company.  
Clearly the major weaknesses are the lack of know-how in this manufacturing process 
and the investment that it represents. Also, economic factors should be taken into 
account both for the opportunities and threats. If it’s true that the economy is starting 
to grow again, uncertainty around the Greek situation and the agitated European 
political scenario can affect negatively the economic and consequently the investment 
capacity of the companies. 
On the other side, Bluepharma has already a very substantial scientific knowledge 
concerning this technology. The fact that it’s still a recent dosage form and that there 
are few products on the market it’s an opportunity. Plus, Bluepharma it’s a company 
dedicated to the external market, which together with its FDA approved manufacturing 
facility can be a good advantage. Figure 35, bellow, displays the S.W.O.T. analysis made 
for this project.  
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Figure 35 - Bluepharma's OTFs project S.W.O.T. analysis. 
Bluepharma is a young and ambitious company, which has already a history of success. 
The Oral Thin Film technology represents an opportunity which can take the company 
to play in a completely different level. But like all great opportunities, there is a risk 
associated. The path made so far resulted in good results and makes the company look 
to the future with hope and expectation. It’s important that the good work can be 
maintained, and that the market possibilities can be continuously updated and 
evaluated. Only well based decisions can reduce its inherent risks. 
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